WO2005024044A2 - Method for the production of fusion proteins in transgenic mammal milk - Google Patents
Method for the production of fusion proteins in transgenic mammal milk Download PDFInfo
- Publication number
- WO2005024044A2 WO2005024044A2 PCT/US2004/029128 US2004029128W WO2005024044A2 WO 2005024044 A2 WO2005024044 A2 WO 2005024044A2 US 2004029128 W US2004029128 W US 2004029128W WO 2005024044 A2 WO2005024044 A2 WO 2005024044A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fusion protein
- protein
- cell
- seq
- human
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 171
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 165
- 238000000034 method Methods 0.000 title claims abstract description 151
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 83
- 235000013336 milk Nutrition 0.000 title claims abstract description 69
- 210000004080 milk Anatomy 0.000 title claims abstract description 69
- 239000008267 milk Substances 0.000 title claims abstract description 69
- 238000004519 manufacturing process Methods 0.000 title claims description 47
- 241000124008 Mammalia Species 0.000 title claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 211
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 173
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 90
- 241001465754 Metazoa Species 0.000 claims abstract description 80
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 80
- 229920001184 polypeptide Polymers 0.000 claims abstract description 77
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 claims abstract description 45
- 102000046101 human AFP Human genes 0.000 claims abstract description 45
- 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 claims abstract description 41
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 39
- 239000012634 fragment Substances 0.000 claims abstract description 16
- 235000018102 proteins Nutrition 0.000 claims description 166
- 210000004027 cell Anatomy 0.000 claims description 138
- 239000013598 vector Substances 0.000 claims description 51
- 108010076119 Caseins Proteins 0.000 claims description 46
- 150000001413 amino acids Chemical group 0.000 claims description 43
- 102000011632 Caseins Human genes 0.000 claims description 42
- 108020004414 DNA Proteins 0.000 claims description 42
- 150000007523 nucleic acids Chemical group 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 31
- 108700019146 Transgenes Proteins 0.000 claims description 29
- 238000012546 transfer Methods 0.000 claims description 28
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 27
- 108090000935 Antithrombin III Proteins 0.000 claims description 25
- 230000004071 biological effect Effects 0.000 claims description 25
- 108090000467 Interferon-beta Proteins 0.000 claims description 23
- 102000004411 Antithrombin III Human genes 0.000 claims description 22
- 241000283690 Bos taurus Species 0.000 claims description 22
- 229960005348 antithrombin iii Drugs 0.000 claims description 22
- 108091033319 polynucleotide Proteins 0.000 claims description 22
- 102000040430 polynucleotide Human genes 0.000 claims description 22
- 239000002157 polynucleotide Substances 0.000 claims description 22
- 210000001519 tissue Anatomy 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 18
- 102000003996 Interferon-beta Human genes 0.000 claims description 17
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 17
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 230000028327 secretion Effects 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 108091026890 Coding region Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 12
- 230000002068 genetic effect Effects 0.000 claims description 12
- 210000004962 mammalian cell Anatomy 0.000 claims description 12
- 210000001161 mammalian embryo Anatomy 0.000 claims description 12
- 201000006417 multiple sclerosis Diseases 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 235000021247 β-casein Nutrition 0.000 claims description 12
- 102000006992 Interferon-alpha Human genes 0.000 claims description 11
- 108010047761 Interferon-alpha Proteins 0.000 claims description 11
- 102000008192 Lactoglobulins Human genes 0.000 claims description 10
- 108010060630 Lactoglobulins Proteins 0.000 claims description 10
- 229960000182 blood factors Drugs 0.000 claims description 10
- 230000001766 physiological effect Effects 0.000 claims description 10
- 108010057464 Prolactin Proteins 0.000 claims description 9
- 102000003946 Prolactin Human genes 0.000 claims description 9
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 9
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 9
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 9
- 229940097325 prolactin Drugs 0.000 claims description 9
- 210000001082 somatic cell Anatomy 0.000 claims description 9
- 102000008857 Ferritin Human genes 0.000 claims description 8
- 108050000784 Ferritin Proteins 0.000 claims description 8
- 238000008416 Ferritin Methods 0.000 claims description 8
- 229960000074 biopharmaceutical Drugs 0.000 claims description 8
- 210000004940 nucleus Anatomy 0.000 claims description 8
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 7
- 108090000738 Decorin Proteins 0.000 claims description 7
- 102000004237 Decorin Human genes 0.000 claims description 7
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims description 7
- 108020004511 Recombinant DNA Proteins 0.000 claims description 7
- 102100026720 Interferon beta Human genes 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 6
- 229940122601 Esterase inhibitor Drugs 0.000 claims description 5
- 108010054218 Factor VIII Proteins 0.000 claims description 5
- 102000001690 Factor VIII Human genes 0.000 claims description 5
- 108010014173 Factor X Proteins 0.000 claims description 5
- 108010063045 Lactoferrin Proteins 0.000 claims description 5
- 102000010445 Lactoferrin Human genes 0.000 claims description 5
- 108090000778 Platelet factor 4 Proteins 0.000 claims description 5
- 102000004211 Platelet factor 4 Human genes 0.000 claims description 5
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 5
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 5
- 210000003855 cell nucleus Anatomy 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000002329 esterase inhibitor Substances 0.000 claims description 5
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 5
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 5
- 229940078795 lactoferrin Drugs 0.000 claims description 5
- 235000021242 lactoferrin Nutrition 0.000 claims description 5
- 206010028417 myasthenia gravis Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 229960005356 urokinase Drugs 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 238000002105 Southern blotting Methods 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 108700027921 interferon tau Proteins 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 241000235070 Saccharomyces Species 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- 208000002458 carcinoid tumor Diseases 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- 102100022977 Antithrombin-III Human genes 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims 3
- 208000028990 Skin injury Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 102000005720 Glutathione transferase Human genes 0.000 claims 1
- 108010070675 Glutathione transferase Proteins 0.000 claims 1
- 206010051246 Photodermatosis Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 230000008845 photoaging Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 73
- 230000004927 fusion Effects 0.000 abstract description 46
- 230000001225 therapeutic effect Effects 0.000 abstract description 22
- 239000013612 plasmid Substances 0.000 abstract description 12
- 210000005075 mammary gland Anatomy 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 230000004481 post-translational protein modification Effects 0.000 abstract description 5
- 230000009435 amidation Effects 0.000 abstract description 4
- 238000007112 amidation reaction Methods 0.000 abstract description 4
- 210000001124 body fluid Anatomy 0.000 abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 2
- 238000003450 affinity purification method Methods 0.000 abstract 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 55
- 102000039446 nucleic acids Human genes 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 24
- 241000283707 Capra Species 0.000 description 20
- 210000000287 oocyte Anatomy 0.000 description 20
- 102000014150 Interferons Human genes 0.000 description 18
- 108010050904 Interferons Proteins 0.000 description 18
- 125000000539 amino acid group Chemical group 0.000 description 18
- 229940079322 interferon Drugs 0.000 description 17
- 108020004635 Complementary DNA Proteins 0.000 description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 238000010804 cDNA synthesis Methods 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 239000003550 marker Substances 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- -1 urine Substances 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 239000013060 biological fluid Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000001605 fetal effect Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 9
- 102000004407 Lactalbumin Human genes 0.000 description 9
- 108090000942 Lactalbumin Proteins 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 235000021240 caseins Nutrition 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 108010011756 Milk Proteins Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 101710087237 Whey acidic protein Proteins 0.000 description 7
- 239000005018 casein Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 102000014171 Milk Proteins Human genes 0.000 description 6
- 241000713333 Mouse mammary tumor virus Species 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 235000021239 milk protein Nutrition 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102000006601 Thymidine Kinase Human genes 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 239000005862 Whey Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000006651 lactation Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 235000021241 α-lactalbumin Nutrition 0.000 description 5
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 108091036066 Three prime untranslated region Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000004019 antithrombin Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 229940021722 caseins Drugs 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000007159 enucleation Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000031864 metaphase Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 235000021246 κ-casein Nutrition 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 3
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 102100030304 Platelet factor 4 Human genes 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 235000013930 proline Nutrition 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- CHFFHQUVXHEGBY-GARJFASQSA-N Ala-Lys-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CHFFHQUVXHEGBY-GARJFASQSA-N 0.000 description 2
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108050001786 Alpha-s2 casein Proteins 0.000 description 2
- 102000018616 Apolipoproteins B Human genes 0.000 description 2
- 108010027006 Apolipoproteins B Proteins 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 101000741059 Bos taurus Alpha-S2-casein Proteins 0.000 description 2
- 101000946377 Bos taurus Alpha-lactalbumin Proteins 0.000 description 2
- 101000741065 Bos taurus Beta-casein Proteins 0.000 description 2
- 101001008231 Bos taurus Beta-lactoglobulin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100012844 Homo sapiens AFP gene Proteins 0.000 description 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 101000895752 Rattus norvegicus Alpha-S2-casein-like A Proteins 0.000 description 2
- 101000947125 Rattus norvegicus Beta-casein Proteins 0.000 description 2
- 101000667278 Rattus norvegicus Whey acidic protein Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102000008847 Serpin Human genes 0.000 description 2
- 108050000761 Serpin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 2
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004880 lymph fluid Anatomy 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 210000004508 polar body Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 208000008864 scrapie Diseases 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HGHOBRRUMWJWCU-FXQIFTODSA-N (4s)-4-[[(2s)-2-aminopropanoyl]amino]-5-[[(2s)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O HGHOBRRUMWJWCU-FXQIFTODSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- BAMUEXIPKSRTBS-UHFFFAOYSA-N 1,1-dichloro-1,2,2,2-tetrafluoroethane Chemical compound FC(F)(F)C(F)(Cl)Cl BAMUEXIPKSRTBS-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LQGNCUXDDPRDJH-UHFFFAOYSA-N 3'-GMP Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)C)CCC33O)C)C3=CC(=O)C21 LQGNCUXDDPRDJH-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- NMXKFWOEASXOGB-QSFUFRPTSA-N Ala-Ile-His Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NMXKFWOEASXOGB-QSFUFRPTSA-N 0.000 description 1
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 1
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 1
- DHBKYZYFEXXUAK-ONGXEEELSA-N Ala-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 DHBKYZYFEXXUAK-ONGXEEELSA-N 0.000 description 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 101710154825 Aminoglycoside 3'-phosphotransferase Proteins 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- SWLOHUMCUDRTCL-ZLUOBGJFSA-N Asn-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N SWLOHUMCUDRTCL-ZLUOBGJFSA-N 0.000 description 1
- IDUUACUJKUXKKD-VEVYYDQMSA-N Asn-Pro-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O IDUUACUJKUXKKD-VEVYYDQMSA-N 0.000 description 1
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 1
- ATYWBXGNXZYZGI-ACZMJKKPSA-N Asp-Asn-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O ATYWBXGNXZYZGI-ACZMJKKPSA-N 0.000 description 1
- VSMYBNPOHYAXSD-GUBZILKMSA-N Asp-Lys-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O VSMYBNPOHYAXSD-GUBZILKMSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000770536 Bacillus thermophilus Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 101000757317 Bos taurus Antithrombin-III Proteins 0.000 description 1
- 101000761239 Bos taurus Kappa-casein Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000168726 Dictyostelium discoideum Species 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- DYFJZDDQPNIPAB-NHCYSSNCSA-N Glu-Arg-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O DYFJZDDQPNIPAB-NHCYSSNCSA-N 0.000 description 1
- PMSDOVISAARGAV-FHWLQOOXSA-N Glu-Tyr-Phe Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 PMSDOVISAARGAV-FHWLQOOXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 1
- FIQQRCFQXGLOSZ-WDSKDSINSA-N Gly-Glu-Asp Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FIQQRCFQXGLOSZ-WDSKDSINSA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 101000946384 Homo sapiens Alpha-lactalbumin Proteins 0.000 description 1
- 101000757319 Homo sapiens Antithrombin-III Proteins 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101001000206 Homo sapiens Decorin Proteins 0.000 description 1
- 101000687438 Homo sapiens Prolactin Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 101710201349 Metallothionein B Proteins 0.000 description 1
- 102100031347 Metallothionein-2 Human genes 0.000 description 1
- 101710094505 Metallothionein-2 Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- LRJUYAVTHIEHAI-UHFFFAOYSA-N Muristeron A Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)C)CCC33O)C)C3=CC(=O)C21O LRJUYAVTHIEHAI-UHFFFAOYSA-N 0.000 description 1
- LRJUYAVTHIEHAI-LHBNDURVSA-N Muristerone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H]([C@H](O)C[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@]21O LRJUYAVTHIEHAI-LHBNDURVSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101100336468 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gem-1 gene Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XUSDDSLCRPUKLP-QXEWZRGKSA-N Pro-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 XUSDDSLCRPUKLP-QXEWZRGKSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- FIXILCYTSAUERA-FXQIFTODSA-N Ser-Ala-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FIXILCYTSAUERA-FXQIFTODSA-N 0.000 description 1
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
- 101710185500 Small t antigen Proteins 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 102000018614 Uromodulin Human genes 0.000 description 1
- 108010027007 Uromodulin Proteins 0.000 description 1
- 102000012349 Uroplakins Human genes 0.000 description 1
- 108010061861 Uroplakins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- VRGWBRLULZUWAJ-XFFXIZSCSA-N [(2s)-2-[(1r,3z,5s,8z,12z,15s)-5,17-dihydroxy-4,8,12,15-tetramethyl-16-oxo-18-bicyclo[13.3.0]octadeca-3,8,12,17-tetraenyl]propyl] acetate Chemical compound C1\C=C(C)/CC\C=C(C)/CC[C@H](O)\C(C)=C/C[C@@H]2C([C@@H](COC(C)=O)C)=C(O)C(=O)[C@]21C VRGWBRLULZUWAJ-XFFXIZSCSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010084217 alanyl-glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000012769 bulk production Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011082 depyrogenation Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VRGWBRLULZUWAJ-UHFFFAOYSA-N fusaproliferin Natural products C1C=C(C)CCC=C(C)CCC(O)C(C)=CCC2C(C(COC(C)=O)C)=C(O)C(=O)C21C VRGWBRLULZUWAJ-UHFFFAOYSA-N 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 101150028578 grp78 gene Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 102000045840 human DCN Human genes 0.000 description 1
- 102000052196 human PF4 Human genes 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940090213 lutalyse Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 101150008049 mx gene Proteins 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 231100000052 myelotoxic Toxicity 0.000 description 1
- 230000002556 myelotoxic effect Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229930185346 proliferin Natural products 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/101—Bovine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Definitions
- the present invention relates to the production of bi-functional fusion proteins which are biologically active and can be used pharmaceutically.
- the cunent invention provides for the production of a ⁇ -interferon and ⁇ -fetoprotein fusion protein sequences linked to a recombinant human Alpha-Fetoprotein sequence in the milk of transgenic mammals, particularly non-human placental mammals and provides for the use of such fusion proteins in therapeutic applications or disease conditions.
- the present invention relates generally to the field of the transgenic production of fusion proteins in the milk of transgenic animals. More particularly, it concerns improved methods for generating transgenic non-human mammalian animals, of various species, capable of producing a variety of fusion proteins of interest. [003] Cunently, there are numerous polypeptides, macromolecules and/or proteins ("proteins of interest") possessing one or more potential therapeutic activities cannot be exploited pharmaceutically.
- the present invention makes it possible to overcome these disadvantages.
- the instant invention provides new fusion molecules which permits the exploitation of the physiological properties or effects of the proteins of interest.
- the present invention results especially from the demonstration that it is possible to fuse a physiologically active sequence derived from a biologically active protein to another recombinant protein structure consisting of a protein sequence retaining the physiological activity of human alpha-fetoprotein to derive a bi-functional fusion protein, without impairing the biological properties of either the alpha-fetoprotein or the second protein moiety thereof. It also results from the demonstration by the Inventors that the recombinant human alpha-fetoprotein protein sequence of the invention ("AFP”) can improve the half-life of the fusion proteins of the invention, and add synergistic therapeutic efficacy as well. [005] The physiological effects of AFP have been shown in the prior art to include both stimulative and inhibitory effects on various cell types.
- AFP can inhibit the growth of many types of tumor cells, and, in particular, inhibits estrogen-stimulated or estrogen-sensitive cell growth. Conversely, AFP stimulates the growth of normal embryonic fibroblasts. AFP has also been shown to have both immunosuppressive and immunoproliferative effects. Therefore the therapeutic effectiveness of an AFP fusion protein can be utilized in such a way as to maximize the pharmacologic effectiveness of treatments for various disease states, especially using bi-functional molecules.
- the fusion proteins according to the cunent invention make it possible to maintain, in the body of an animal, a desirable biological activity for a prolonged period.
- the proteins of interest according to the cunent invention can also be expressed secreted by recombinant organisms, such as in cell culture production facilities, or transgenic mammals, at levels permitting their commercial exploitation.
- transgenic mammals are a prefened manufacturing and expression vehicle for the fusion proteins of the invention.
- Mammals having certain desired traits or characteristics, such as increased weight, milk content, milk production volume, length of lactation interval and disease resistance have long been desired.
- Traditional breeding processes are capable of producing animals with some specifically desired traits, but often these traits these are often accompanied by a number of undesired characteristics, and are often too time- consuming, costly and unreliable to develop.
- transgenic animals are animals that carry the gene(s) of interest that has been deliberately introduced into existing somatic cells and/or germ line cells at an early stage of development.
- the cunent invention provides for the bulk production of a bi-functional fusion protein of interest in the milk of transgenic mammals.
- the production of a fusion protein of interest in milk is ideal as a bulk process because very large volumes of milk that can be produced, collected and purified using known dairy technology.
- a second advantage of using a transgenic mammalian process is that some reactions which can be essential for biological activity in humans, for example carboxy-terminal amidation, are difficult to perform in good yield by cunently available chemical means or in bacterial or other in vitro situations.
- carboxy-terminal amidation is catalyzed by a specific enzyme which recognizes and modifies a fusion protein of interest or proteins with a glycine residue at the carboxy terminus. Therefore, suitably designed fusion proteins of the invention can be specifically amidated before secretion into the milk of transgenic animals.
- This is only one example of a range of post-translational modifications which can be carried out by the biosynthetic pathways in the mammary gland and which can potentially be harnessed for the synthesis of particular fusion proteins.
- Other examples of desirable post-translational modifications include di-sulfide bridge formation, ⁇ -carboxylation of glutamic acid residues and the addition of O- and N-linked glycosylation.
- non-glycosylated form of recombinant AFP exhibits similar biological properties to the normally glycosylated form and provides a standardized consistent product due to the lack of glycosylation variability. It may also be more easily produced in in vitro or transgenic systems. Therefore, non-glycosylated AFP is a prefened form for commercial production. [0010] According to the prior art, the generation of an animal capable of producing a recombinant protein of interest is known.
- the cunent invention provides a method for the production of bi-functional fusion proteins of interest, preferably through the use of transgenic animals.
- the method involves transfecting a non-human mammalian cell- line with a given transgene construct, the construct containing at least one recombinant DNA coding sequence encoding a desired first desired peptide fragment and a second desired peptide fragment each of which retain the biological activity of an individual protein of interest.
- the process involves developing the DNA construct; selecting a cell line(s) in which the desired recombinant sequence has been inserted into the genome of that cell or cell-line; performing a nuclear transfer procedure to generate a transgenic animal heterozygous for the desired fusion protein.
- the fusion protein expressing the bi-functional fusion protein may be collected from the milk or other bodily fluid of the transgenic animal and purified for use as a therapeutic agent.
- An additional step that may be performed according to the invention is to biopsy the heterozygous transgenic animal. Thereafter, according to the cunent invention the cell line can be expanded in vitro with the biopsied cell-line obtained from the heterozygous animal used to develop multiple transgenic animals in a shorter time period.
- a nuclear transfer procedure can be conducted to generate a mass of transgenic cells useful for research, serial cloning, or other in vitro use.
- surviving cells are characterized by one of several known molecular biology methods including without limitation FISH, Southern Blot, or PCR.
- the methods provided above will allow for the accelerated production of a fransgenic herd of animals homozygous for desired fransgene(s) and thereby the more efficient production of a desired biopharmaceutical.
- the cunent invention allows for the production of genetically desirable livestock or non-human mammals themselves expressing a bi- functional fusion protein of interest.
- the methods of the cunent invention will also allow the development of one or more homozygous animals that carry a particularly beneficial or valuable fusion protein, potentially increasing herd yield of a desired protein much more quickly than previous methods.
- the methods of the cunent invention will also provide for the replacement of specific fransgenic animals lost through disease or their own mortality. They will also facilitate and accelerate the production of transgenic animals constructed with a variety of DNA constructs so as to optimize the production and lower the cost for the production of a desirable biopharmaceutical composition. [0016] Therefore according to an embodiment of the cunent invention it may be useful to make transgenic animals homozygous for a fusion protein of interest. In this embodiment it is preferable that the transgene of interest and the genetic composition of the heterozygous transgenic animal are characterized.
- One subject of the present invention therefore relates to bi-functional fusion proteins containing an active part derived from a peptide fragment having a therapeutic activity, coupled to a human alpha-fetoprotein or a variant of human alpha- fetoprotein having a separate and, in some cases, synergistic effect.
- Another subject of the invention relates to a process for preparing the chimeric molecules described above.
- this process consists in causing a eukaryotic or prokaryotic cellular host to express a nucleotide sequence encoding the desired fusion protein, and then in harvesting the fusion protein product.
- a medicament that is capable of treating myasthenia gravis.
- FIG. 1 Shows a flowchart of the methods involved in practicing the invention.
- FIG. 2 Shows a Generalized Diagram of the Process of Creating Cloned Animals through Nuclear Transfer.
- FIG. 3 Shows a diagram of the amino acid sequence of ⁇ -interferon.
- FIG. 4 Shows a fusion protein of interest
- the protein secretory signal is cleaved from AFP during processing or maturation processes;
- Biological Activity/Physiological Activity - is intended to be interpreted broadly.
- interferon-like proteins it includes all known (or to be discovered) properties including properties specific to human IFN- ⁇ 's or to human IFN- ⁇ , or common to both, such as their antiviral activity and their capability to modulate antigens of the major histocompatibility complex (MHC).
- MHC major histocompatibility complex
- Biological Fluid - an aqueous solution produced by an organism, such as a mammal, bird, amphibian, or reptile, which contains proteins that are secreted by cells that are bathed in the aqueous solution.
- an organism such as a mammal, bird, amphibian, or reptile
- proteins that are secreted by cells that are bathed in the aqueous solution.
- examples include: milk, urine, saliva, seminal fluid, vaginal fluid, synovial fluid, lymph fluid, amniotic fluid, blood, sweat, and tears; as well as an aqueous solution produced by a plant, including, for example, exudates and guttation fluid, xylem, phloem, resin, and nectar.
- Biological-fluid producing cell - A cell that is bathed by a biological fluid and that secretes a protein into the biological fluid.
- Biopharmaceutical shall mean any medicinal drug, therapeutic, vaccine or any medically useful composition whose origin, synthesis, or manufacture involves the use of microorganisms, recombinant animals (including, without limitation, chimeric or transgenic animals), nuclear transfer, microinjection, or cell culture techniques.
- Encoding - refers generally to the sequence information being present in a translatable fonn, usually operably linked to a promoter (e.g., a beta- casein or beta-lacto globulin promoter).
- a sequence is operably linked to a promoter when the functional promoter enhances transcription or expression of that sequence.
- An anti-sense strand is considered to also encode the sequence, since the same informational content is present in a readily accessible form, especially when linked to a sequence which promotes expression of the sense strand.
- the information is convertible using the standard, or a modified, genetic code.
- Expression Vector - A genetically engineered plasmid or virus, derived from, for example, a bacteriophage, adenovirus, retrovirus, poxvirus, herpesvirus, or artificial chromosome, that is used to fransfer an AFP fusion protein coding sequence, operably linked to a promoter, into a host cell, such that the encoded recombinant AFP fusion protein is expressed within the host cell.
- Fusion Slide A glass slide for parallel electrodes that are placed a fixed distance apart. Cell couplets are placed between the electrodes to receive an electrical cunent for fusion and activation.
- Homologous Sequences refers to genetic sequences that, when compared, exhibit similarity.
- the standards for homology in nucleic acids are either measures for homology generally used in the art or hybridization conditions.
- Substantial homology in the nucleic acid context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or deletions, in at least about 60% of the residues, usually at least about 10%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95 to 98% of the nucleotides.
- substantial homology exists when the segments will hybridize under selective hybridization conditions, to a strand, or its complement.
- Selectivity of hybridization exists when hybridization occurs which is more selective than total lack of specificity. Typically, selective hybridization will occur when there is at least about 55% homology over a stretch of at least about 14 nucleotides, preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90%.
- Human alpha-fetoprotein or "AFP" or “rAFP” - a peptide having substantially the same amino acid sequence as the mature alpha-fetoprotein (amino acids 19-609) set forth in Genbank Accession No. V01514 (SEQ ID NO: 4) and encoded by nucleotides 99-1874 of the cDNA sequence set forth in Genbank Accession No. V01514 (SEQ ID NO: 3) and reported in Morinaga et al. (PROC. NATL. ACAD. Sci. USA 80:4604-4608, (1983)).
- Human alpha-fetoprotein precursor - a peptide having substantially the same amino acid sequence as amino acids 1-609 set forth in Genbank Accession No. V01514 (SEQ ED NO: 2) and encoded by nucleotides 45- 1874 of the cDNA sequence set forth in Genbank Accession No. V01514 (SEQ ID NO: 1).
- Leader sequence or a "signal sequence" a nucleic acid sequence that encodes a protein secretory signal, and, when operably linked to a downstream nucleic acid molecule encoding an AFP fusion protein and directs AFP secretion.
- the leader sequence may be the native human AFP leader, an artificially-derived leader, or may obtained from the same gene as the promoter used to direct transcription of the AFP coding sequence, or from another protein that is normally secreted from a cell.
- Milk-producing cell - A cell (e.g., a mammary epithelial cell) that secretes a protein into milk.
- Milk-specific promoter - A promoter that naturally directs expression of a gene in a cell that secretes a protein into milk e.g., a mammary epithelial cell
- the casein promoters e.g., alpha casein promoter (e.g., alpha S-l casein promoter and alpha S2-casein promoter), beta casein promoter (e.g., the goat beta casein gene promoter (DiTullio, BIOTECHNOLOGY 10:74-77, 1992), gamma casein promoter, and kappa casein promoter; the whey acidic protein (WAP) promoter (Gorton et al., BIOTECHNOLOGY 5: 1183-1187, 1987); the beta-lactoglobulin promoter (Clark et al., BIOTECHNOLOGY 7: 487-492, 1989); and the alpha-lactalbumin promoter (Soulier et al., FEBS LET
- the nucleic acid sequence of the precursor non-glycosylated human alpha- fetoprotein includes nucleotides 45 through 1874 of the sequence set forth in SEQ ID NO: 5.
- Nuclear Transfer - refers to a method of cloning wherein the nucleus from a donor cell is transplanted into an enucleated oocyte.
- Operably Linked - A gene and one or more regulatory sequences are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequences.
- Parthenogenic The development of an embryo from an oocyte without the penetration of sperm.
- compositions suitable for unequivocal biological testing as well as for appropriate administration to effect treatment of a human patient refers to fusion protein that is suitable for unequivocal biological testing as well as for appropriate administration to effect treatment of a human patient.
- substantially pharmaceutically pure means at least about 90%> pure.
- Porcine - of or resembling pigs or swine Porcine - of or resembling pigs or swine.
- Promoter - A minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell type-specific, tissue-specific, temporal-specific, or inducible by eexxtteerrnnaall ssiiggnnaallss oorr aaggeennttss;; ssuucchn eelieemmeennts may be located in the 5' or 3' or i inntfrrnonn s spemquiRenrcPe. r rfiegoiinonnus n offt tthipe
- Protein - as used herein is intended to include glycoproteins, as well as proteins having other additions. This also includes fragmentary or truncated polypeptides that retain physiological function.
- Recombinant - refers to a nucleic acid sequence which is not naturally occurring, or is made by the artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by either chemical synthesis means, or by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques. Such is usually done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functional polypeptide sequences to generate a single genetic entity comprising a desired combination of functions not found in the common natural forms.
- Restriction enzyme recognition sites are often the target of such artificial manipulations, but other site specific targets, e.g., promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may be incorporated by design.
- site specific targets e.g., promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may be incorporated by design.
- a similar concept is intended for a recombinant, e.g., a bi-functional fusion protein according to the instant invention.
- Therapeutically-effective amount An amount of a therapeutic molecule or a fragment thereof that, when administered to a patient, inhibits or i stimulates a biological activity modulated by that molecule.
- Transformation Any method for introducing foreign molecules into a cell. Lipofection, DEAE-dextran- mediated transfection, microinjection, nuclear transfer (see, e.g., Campbell et al. BIOL. REPROD. 49:933-942, 1993; Campbell et al., NATURE 385:810-813, 1996), protoplast fusion, calcium phosphate precipitation, transduction (e.g., bacteriophage, adenoviral refroviral, or other viral delivery), electroporation, and biolistic transformation are just a few of the methods known to those skilled in the art which may be used.
- the nucleic acid molecule may be stably incorporated into the host chromosome, or may be maintained episomally.
- Transgene Any piece of a nucleic acid molecule that is inserted by artifice into a cell, or an ancestor thereof, and becomes part of the genome of the animal which develops from that cell.
- a transgene may include a gene which is partly or entirely exogenous (i.e., foreign) to the fransgenic animal, or may represent a gene having identity to an endogenous gene of the animal.
- Transgenic Organism An organism into which genetic material from another organism has been experimentally transfened, so that the host acquires the genetic information of the transfened genes in its chromosomes in addition to that already in its genetic complement.
- Ungulate - of or relating to a hoofed typically herbivorous quadruped mammal, including, without limitation, sheep, swine, goats, cattle and horses.
- Vector - As used herein means a plasmid, a phage DNA, or other DNA sequence that (1) is able to replicate in a host cell, (2) is able to transform a host cell, and (3) contains a marker suitable for identifying transformed cells.
- a method for the production of a fusion protein of interest comprising expressing in the milk of a fransgenic non-human placental mammal a fusion protein comprising a first polypeptide of interest linked to a second polypeptide of interest both of which have independent physiological effects.
- One protein family of interest for use in the bi-functional molecule of the cunent invention is the interferon family of proteins. Interferon's ("IFN's") constitute a group of naturally occurring proteins which are known to exhibit antiviral, anti-tumor and immunoregulatory behavior. This class of cytokines has immune stimulating/modulating activity.
- IFN's Interferon's
- interferon's are a family of small proteins and glycoprotein's with molecular weights of approximately 15,000 to 28,000 Daltons (15- 28 kDa) produced and secreted in vivo by cells primarily in response to viral infection, and also in response to synthetic or biological inducers.
- the nomenclature conventions used to describe and name interferon's is complex. This is largely due to advancing knowledge and technology which has shown various interferons's to be produced by the same cell types, the discovery of different species and forms of interferon, and the discovery that some forms are identical to others previously reported. Because human native interferon has long been expensive to extract, techniques have been developed for preparing recombinant forms of human interferon.
- Interferon's exert their cellular activities by binding to specific membrane receptors on the cell surface. Once bound to the cell membrane, interferon's initiate a complex sequence of intracellular events, including the up-regulation of certain other cytdkines, induction of certain enzymes, suppression of cell proliferation, immunomodulating activities such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes (e.g., cellular immunity) for target cells, and inhibition of virus replication in virus-infected cells.
- a range of biological activities are associated with IFNs including antiviral, anti-proliferative and immunoregulatory activities.
- Therapeutic uses include the treatment of Hairy Cell leukemia, Chronic myelogenous leukemia, low grade non- Hodgkin lymphoma, cutaneous T cell lymphoma carcinoid tumors, renal cell carcinoma, squamous epithelial tumors of the head and neck, multiple myeloma, and malignant melanoma.
- IFN- ⁇ has been found to aid the treatment of chronic active hepatitis, caused by either Hepatitis B or C viruses.
- FDA Food and Drug Administration
- IFN- ⁇ beta interferon
- MS is an autoimmune disease, in which the body's defense system attacks the myelin sheath, the fatty substance that protects nerve fibers of the brain and spinal cord much as insulation covers electrical wire. The transmission of electrical impulses to and from the brain is disrupted as MS lesions create breaks in the myelin sheath. As a result, people with MS experience symptoms including weakness, fatigue, incontinence, visual impairment, sluned speech, or sometimes paralysis.
- Beta interferon has been shown in the prior art to positively effect the treatment of multiple sclerosis. Ambulatory patients with relapsing-remitting MS who took high doses of beta interferon had about 30% fewer attacks, and half as many severe ones, as people who took a placebo. Therefore, a molecule of interest made through the methods of the cunent invention is an AFP -IFN- ⁇ bi-functional fusion protein, with beneficial synergistic effects when used therapeutically against MS. That is, the therapeutic effect of ⁇ -EFN is synergistically heightened by the presence of a functional alpha-fetoprotein moiety- itself having beneficial effectiveness against MS. [0036] Suitable host organisms for possible prokaryotic or eukaryotic in vitro production include: E.
- the fusion proteins expressed in accordance with the present invention may be glycosylated or unglycosylated depending on the glycosylation occurring in the host organism used to produce the protein and the DNA sequence of the genetically engineered sequences according to the cunent invention. If desired, unglycosylated the expressed protein obtained when E. coli. or a Bacillus is the host organism may be optionally glycosylated in vitro by chemical, enzymatic and other types of modifications known in the art.
- transgenic primary cell line from either caprine, bovine, ovine, porcine or any other non-human vertebrate origin
- fusion protein nucleic acid construct of interest for example, a mammary gland-specific transgene(s) targeting expression of a human alpha-fetoprotein - ⁇ -interferon fusion protein to the mammary gland.
- the transgene construct can either contain a selection marker (such as neomycin, kanamycin, tetracycline, puromycin, zeocin, hygromycin or any other selectable marker) or be co- transfected with a cassette able to express the selection marker in cell culture.
- a selection marker such as neomycin, kanamycin, tetracycline, puromycin, zeocin, hygromycin or any other selectable marker
- the invention provides expression vectors containing a nucleic acid sequence described herein, operably linked to at least one regulatory sequence. Many such vectors are commercially available, and other suitable vectors can be readily prepared by the skilled artisan. "Operably linked” or "operatively linked” is intended to mean that the nucleic acid molecule is linked to a regulatory sequence in a manner which allows expression of the nucleic acid sequence by a host organism.
- regulatory sequences are art recognized and are selected to produce the encoded polypeptide or protein. Accordingly, the term “regulatory sequence” includes promoters, enhancers, and other expression control elements which are described in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, (Academic Press, San Diego, Calif. (1990)). For example, the native regulatory sequences or regulatory sequences native to the transformed host cell can be employed. [0039] It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed.
- the polypeptides of the present invention can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells or both.
- a vector suitable for expression in either prokaryotic cells, eukaryotic cells or both A LABORATORY MANUAL, 2nd Ed., ed. Sambrook et al. (Cold Spring Harbor Laboratory Press, 1989) Chapters 16 and 17)).
- cells are isolated and expanded, with aliquots frozen for long-term preservation according to procedures known in the field.
- the selected transgenic cell- lines can be characterized using standard molecular biology methods (PCR, Southern blotting, FISH).
- Cell lines canying nucleic acid constructs of the bi-functional fusion protein of interest, of the appropriate copy number, generally with a single integration site (although the same technique could be used with multiple integration sites) can then be used as karyoplast donors in a somatic cell nuclear fransfer protocol known in the art. Following nuclear transfer, and embryo transfer to a recipient animal, and gestation, live transgenic offspring are obtained. Typically this fransgenic offspring carries only one transgene integration on a specific chromosome, the other homologous chromosome not canying an integration in the same site. Hence the transgenic offspring is heterozygous for the transgene, maintaining the cunent need for at least two successive breeding cycles to generate a homozygous transgenic animal.
- Example 1 AFP - ⁇ Interferon
- Another feature of the invention is a method of treating a patient in need of the bi-functional fusion protein of the invention by administering to the patient a therapeutically-effective amount of a biological fluid (e.g., milk, urine, saliva, seminal or vaginal fluid, synovial fluid, lymph fluid, amniotic fluid, the fluid within the yolk sac, the chorion, or the allantois of an egg, blood, sweat, and tears; or an aqueous solution produced by a plant, including, for example, exudates or guttation fluid, xylem, phloem, resin, and nectar), or extract thereof, that includes the bi-functional fusion protein of the invention that is obtained from a transgenic non-human organism (e.g., a mammal (e.g., a mouse, goat, sheep, camel, cow, pig, rabbit, horse, ox, or llama), a bird, a reptile,
- the bi- functional protein of the invention has the sequence set forth in the combination of SEQ ID NOS: 4, 10 and 24.
- the biological fluid is milk.
- the bi-functional fusion protein of the invention is purified from the transgenic non-human organism's biological fluid (e.g., the bi-functional fusion protein of the invention purified from the milk, urine, blood, or lymph of a mammal).
- the method may be used to inhibit or treat an immunologic disorder, e.g., infection with the human immunodeficiency virus (HEV), cancer cell growth, to induce bone marrow cell proliferation (for example, after a bone manow transplant or after administration of a myelotoxic treatment such as chemotherapy or radiation treatment), or as an immunosuppressive agent (for example, to inhibit autoreactive immune cell proliferation, to inhibit rejection of a transplanted organ (e.g., graft-versus-host disease), or to inhibit or treat an autoimmune disorder, e.g., rheumatoid arthritis, muscular dystrophy, systemic lupus erythematosus, myasthenia gravis, multiple sclerosis, insulin-dependent diabetes mellitus, or psoriasis), human AFP gene (GenBank Accession #M16110).
- an immunologic disorder e.g., infection with the human immunodeficiency virus (HEV), cancer cell growth
- HEV human immunodeficiency virus
- Seq. Id. 1 The entire cDNA sequence set forth in Genbank Accession No. V01514.
- Seq. Id. 3 Genbank Accession No. V01514 (nucleic acids 99-1874) from the cDNA of Seq. Id. 1.
- Seq. Id. 6 Genbank Accession No. V01514 (amino acids 19-609) except including a mutation at amino acid position 233 of SEQ ID NO: 4 from an asparagine residue to a glutamine residue to remove the single glycosylation site in AFP.
- Seq. Id. 12 Genbank/EMBL /DDBJ Accession No. AAP20099, from the National Center for Biotechnology Information - human ⁇ -interferon variant 2B (1 - 166 amino acid residues) Seq. Id.: 13 Protein Sequence Record Genbank Accession No. NP_795372, from the National Center for Biotechnology Information - human ⁇ -interferon (1 - 189 amino acid residues)
- Seq. Id. 20 Genbank Accession No. 113936 - "cleaved” human antithrombin (1 - 464 amino acid residues) generated by enzyme cleavage of antithrombin between Arginine residue 393 and Serine residue 394.
- Seq. Id. 21 Protein Sequence Record Genbank Accession No. NP_002611, from the National Center for Biotechnology Information - human Platelet Factor 4 (1 - 104 amino acid residues)
- Optimized Codons Expression of protein in a host organism, and most particularly in a transgenic organism, can in part depend on how well the start codon of the DNA construct matches the host organism's optimum (or consensus) start site, how well the mRNA's codon usage matches the "codon bias" of the host organism, the presence of cryptic intron splice sites (potentially resulting in truncated or nonsense proteins), and presence of stabilizing or destabilizing signals (i.e. PEST degradation signals) in the protein of interest.
- Proteins of interest derived from organisms that have a nucleic acid profile highly divergent from that of the host organism may benefit from re-engineering the cDNA sequence so as to optimize codons of key amino acids so that they more closely match the "prefened” or common nucleic acid codons for given amino acids.
- a protein of interest from a high A-T content organism (Dictyostelium discoideum or Plasmodiumfalciparum for example) could more easily be expressed by optimizing the codons towards G-C heavy codons, while leaving the amino acid sequence unchanged.
- the use of optimized expression systems for the production of large quantities of proteins of interest may be necessary to make enough of a compound available to make it therapeutically feasible. To this end it is possible to re-engineer synthetic genes utilizing optimized codons for all of the bi-functional fusion proteins under provided according to the cunent invention.
- fetal cell medium [equilibrated Medium- 199 (Ml 99, Gibco) with 10% fetal bovine serum (FBS) supplemented with nucleosides, 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine and 2
- substantially pure and homogenous describe a protein or polypeptide which has been separated from components which naturally accompany it.
- a monomeric protein is substantially pure when at least about 60 to 75% of a sample exhibits a single polypeptide backbone. Minor variants or chemical modifications typically share the same polypeptide sequence.
- a substantially pure protein will typically comprise over about 85 to 90% of a protein sample, more usually will comprise at least about 95%>, and preferably will be over about 99% pure. Normally, purity is measured on a polyacrylamide gel, with homogeneity determined by staining. For certain purposes high resolution will be used and HPLC or a similar means for purification utilized.
- a protein is substantially free of naturally associated components when it is separated from the native contaminants which accompany it in its natural state.
- a protein which is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components.
- the term is used to describe polypeptides and nucleic acids which have been synthesized in heterologous mammalian cells or plant cells, E. coli. and other prokaryotes.
- the present invention provides for substantially pure preparations for therapeutic use.
- Various methods for their isolation from biological material may be devised, based in part upon the structural and functional descriptions contained herein.
- fusion protein is intended to describe a fused protein comprising two polypeptides of interest fused by a linker sequence amino acid sequence.
- the generation of bi-functional fusion proteins is a useful tool in providing enhanced therapeutic options for specific disease conditions. Therefore the development of needed fusion techniques have become an increasingly important.
- the construction of recombinant fusion proteins has often been used as a means to increase the expression of soluble proteins and to facilitate protein purification. The technique has been used to study the functional activity of proteins in in vitro assays and for in vivo production.
- a wide range of applications of the gene fusion technique have been reported in the field of biotechnology. These applications include the selection and production of antibodies and the engineering of bifunctional enzymes.
- the construction of a fusion protein involves the linking of two macromolecules by a linker sequence.
- the macromolecules of interest include proteins or the globular domains of proteins.
- the selection of the linker sequence is particularly important in the construction of functional fusion proteins, hi addition to the necessity of an appropriate amino acid composition, the overall folding of the linker sequence must be taken into consideration.
- linker sequence with high propensity for forming helix or strand structures, because these would limit the flexibility of the fusion protein and consequently affect its functional activity. Therefore, the design of a linker sequence often requires careful consideration in order to avoid such secondary structural elements.
- a set of sample linker sequences that are known to adopt extended conformations as determined by X-ray crystallography and NMR is provided below:
- the linker sequence useful for the cunent invention comprise at least one amino acid residue or more, those provided above are 12 amino acid residues long.
- the orientation of the first and second polypeptides of interest can be altered according to convenience with the N- terminal sequence of AFP being fused to a linker and the C-terminal end of a second polypeptide of interest or vice versa.
- Two biologically active molecules are fused to provide heightened therapeutic function as well as to enhance molecular half-life. The choice of carrier protein is frequently ruled by the application of the fusion protein constructed.
- AFP functions as a carrier protein polypeptide, while retaining its own therapeutic effects and offering synergistic improvements in activity.
- the joining of the various genomic or cDNA fragments encoding the transgene is performed in accordance with conventional techniques, employing blunt- ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkali and phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases.
- the genetic construct may optionally encode a leader sequence to allow efficient expression of the fusion protein.
- the DNA construct of human AFP is fused to a linker sequence and a second polynucleotide sequence of interest.
- the overall nucleotide sequence may have its codons optimized to enhance expression and/or to be more compatible with the chosen expression platform (ex: transgenic mammal, prokaryote cell culture, mammalian cell culture etc.). Since glycosylation of the fusion protein of interest is a characteristic of the eukaryotic system, a bi-functional recombinant protein sequence useful for therapeutic applications is preferably produced in eukaryotic cells or transgenic mammals. In these production platforms a plasmid selected for amplification of the fusion protein of interest and made transgenic for the cDNA construct of the bi- functional protein of interest may be subcloned into a gene-amplification system of choice.
- a desired fusion protein in mammalian cells is prefened according to the cunent invention in order to ensure the production of biologically functional protein because of factors such as the presence of native leader sequences that ensure successful secretion of the protein, the presence of appropriate folding factors and the capacity for posttranslational modifications.
- the expression of a bi-functional fusion protein in mammalian cells is essential for use in the production of biopharmaceuticals.
- the invention relates to a method of production of peptides having a specifically desired sequence and to the protein and nucleic acid intermediates necessary for the practice of the method.
- the bi-functional fusion protein sequence to be produced can be identical to the desired end product (the peptide of interest) or it can contain one or more tandem copies of the peptide of interest and/or it can contain sequences associated with a selectively cleavable bond.
- the method of the invention comprises the steps of: a) providing a cDNA or genomic DNA construct which encodes a fusion protein having a first polypeptide of interest, a peptide linker sequence and a second polypeptide of interest, which gene is operably connected to a first locus control region and a first promoter; b) making a transgenic animal having the operably connected fusion gene integrated into its genome, whereby the fusion protein is expressed and incorporated into the milk of the transgenic animal upon lactation or hormonal induction of lactation; and c) isolating the fusion protein from the milk of the transgenic animal.
- transgene vectors containing replicon and control sequences derived from species compatible with a host cell are used in connection with the host.
- the vector ordinarily carries a replicon site, as well as specific genes which are capable of providing phenotypic selection in transformed cells.
- the expression of the fusion protein can also be placed under control with other regulatory sequences which may be homologous to the organism in its untransformed state.
- a goat ⁇ -casein promoter can be used which will activate expression of the transgene of interest upon the initiation of lactation.
- Other promoters/operator systems or portions thereof can be employed as well.
- whey acid promoters beta-lactoglobin, alkaline phosphatase, and the like can be used.
- vector systems For mammalian hosts, several possible vector systems are available for initial expression.
- One class of vectors utilize DNA elements which are derived from animal viruses such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retroviruses (RSV, MMTV or MOMLV), or SV40 virus.
- Cells which have stably integrated the DNA into their chromosomes may be selected by introducing one or more markers which allow selection of transfected host cells.
- the marker may provide for protofropy to an auxotrophic host, antibiotic resistance, or resistance to heavy metals such as copper or the like.
- the selectable marker gene can be either directly linked to the DNA sequences to be expressed, or introduced into the same cell by co-transformation. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include splice signals, as well as transcriptional promoters, enhancers, and termination signals.
- Transfected fetal somatic cells were seeded in 4-well plates with fetal cell medium and maintained in culture (5% CO 2 , 39°C). After 48 hours, the medium was replaced with fresh low serum (0.5 % FBS) fetal cell medium. The culture medium was replaced with low serum fetal cell medium every 48 to 72 hours over the next 2 - 7 days following low serum medium, somatic cells (to be used as karyoplast donors) were harvested by trypsinization. The cells were re-suspended in equilibrated M199 with 10% FBS supplemented with 2 mM L-glutamine, 1% penicillin/streptomycin (10,000 I. U.
- the cunent experiments for the generation of desirable transgenic animals are preferably carried out with goat cells or mouse cells for the generation or ( goats or mice respectively but, according to the cunent invention, could be carried out with any mammalian cell line desired.
- Oocyte donor does were synchronized and super ovulated as previously described (Ongeri, et al., 2001), and were mated to vasectomized males over a 48-hour interval. After collection, oocytes were cultured in equilibrated Ml 99 with 10% FBS supplemented with 2 mM L-glutamine and 1% penicillin/streptomycin (10,000 LU. each/ml). Cytoplast Preparation and Enucleation. [0056] All oocytes were treated with cytochalasin-B (Sigma, 5 ⁇ g/ml in SOF with 10%) FBS) 15 to 30 minutes prior to enucleation.
- cytochalasin-B Sigma, 5 ⁇ g/ml in SOF with 10%
- Metaphase-II stage oocytes were enucleated with a 25 to 30 ⁇ m glass pipette by aspirating the first polar body and adjacent cytoplasm sunounding the polar body ( ⁇ 30 % of the cytoplasm) to remove the metaphase plate. After enucleation, all oocytes were immediately reconstructed.
- Donor cell injection was conducted in the same medium used for oocyte enucleation.
- One donor cell was placed between the zona pellucida and the ooplasmic membrane using a glass pipet.
- the cell-oocyte couplets were incubated in SOF for 30 to 60 minutes before electro fusion and activation procedures.
- Reconstructed oocytes were equilibrated in fusion buffer (300 mM mannitol, 0.05 mM CaCl 2 , 0.1 mM MgSO 4 , 1 mM K 2 HPO 4 , 0.1 mM glutathione, 0.1 mg/ml BSA) for 2 minutes.
- fusion buffer 300 mM mannitol, 0.05 mM CaCl 2 , 0.1 mM MgSO 4 , 1 mM K 2 HPO 4 , 0.1 mM glutathione, 0.1 mg/ml BSA
- Electrofusion and activation were conducted at room temperature, in a fusion chamber with 2 stainless steel electrodes fashioned into a "fusion slide" (500 ⁇ m gap; BTX- Genetronics, San Diego, CA) filled with fusion medium.
- Fusion was perfonned using a fusion slide. The fusion slide was placed inside a fusion dish, and the dish was flooded with a sufficient amount of fusion buffer to cover the electrodes of the fusion slide. Couplets were removed from the culture incubator and washed through fusion buffer. Using a stereomicroscope, couplets were placed equidistant between the electrodes, with the karyoplast/cytoplast junction parallel to the electrodes.
- the voltage range applied to the couplets to promote activation and fusion can be from 1.0 kV/cm to 10.0 kV/cm.
- the initial single simultaneous fusion and activation electrical pulse has a voltage range of 2.0 to 3.0 kV/cm, most preferably at 2.5 kV/cm, preferably for at least 20 ⁇ sec duration.
- This is applied to the cell couplet using a BTX ECM 2001 Electrocell Manipulator.
- the duration of the micropulse can vary from 10 to 80 ⁇ sec.
- the treated couplet is typically transfened to a drop of fresh fusion buffer.
- cytocholasin-B its concentration can vary from 1 to 15 ⁇ g/ml, most preferably at 5 ⁇ g/ml.
- the couplets were incubated at 37-39°C in a humidified gas chamber containing approximately 5% CO 2 in air.
- mannitol may be used in the place of cytocholasin-B throughout any of the protocols provided in the cunent disclosure (HEPES-buffered mannitol (0.3 mm) based medium with Ca +2 and BSA).
- Pregnancy and Perinatal Care were determined by ultrasonography starting on day 25 after the first day of standing estrus. Does were evaluated weekly until day 75 of gestation, and once a month thereafter to assess fetal viability. For the pregnancy that continued beyond 152 days, parturition was induced with 5 mg of PGF2 ⁇ (Lutalyse, Upjohn). Parturition occuned within 24 hours after freatment. kids were removed from the dam immediately after birth, and received heat-treated colostrum within 1 hour after delivery. Time frames appropriate for other ungulates with regard to pregnancy and perinatal care (e.g., bovines) are known in the art.
- Genotyping of Cloned Animals Shortly after birth, blood samples and ear skin biopsies are obtained from cloned animals (e.g., goats or cattle) and the sunogate dams for genomic DNA isolation. According to the cunent invention each sample may be first analyzed by PCR using primers for a specific transgenic target protein, and then subjected to Southern blot analysis using the cDNA for that specific target protein.
- the present invention also includes a method of cloning a genetically engineered or transgenic mammal, by which a desired gene is inserted, removed or modified in the differentiated mammalian cell or cell nucleus prior to insertion of the differentiated mammalian cell or cell nucleus into the enucleated oocyte.
- a genetically engineered or transgenic mammal by which a desired gene is inserted, removed or modified in the differentiated mammalian cell or cell nucleus prior to insertion of the differentiated mammalian cell or cell nucleus into the enucleated oocyte.
- mammals obtained according to the above method, and the offspring of those mammals are also provided by the present invention.
- the present invention is preferably used for cloning caprines or bovines but could be used with any mammalian species.
- the present invention further provides for the use of nuclear transfer fetuses and nuclear transfer and chimeric offspring in the area of cell, tissue and organ transplantation.
- Suitable mammalian sources for oocytes include goats, sheep, cows, pigs, rabbits, guinea pigs, mice, hamsters, rats, primates, etc.
- the oocytes will be obtained from ungulates, and most preferably goats or cattle. Methods for isolation of oocytes are well known in the art. Essentially, this will comprise isolating oocytes from the ovaries or reproductive tract of a mammal, e.g., a goat.
- oocytes may preferably be matured in vivo before these cells may be used as recipient cells for nuclear transfer, and before they can be fertilized by the sperm cell to develop into an embryo.
- Metaphase II stage oocytes which have been matured in vivo, have been successfully used in nuclear transfer techniques. Essentially, mature metaphase II oocytes are collected surgically from either non-super ovulated or super ovulated animals several hours past the onset of estrus or past the injection of human chorionic gonadotropin (hCG) or similar hormone.
- hCG human chorionic gonadotropin
- Fusion proteins capable of being produced in through the method of the invention include those containing an alpha-fetoprotein polypeptide and a fusion protein partner including: antithrombin III, truncated ATIII, lactoferrin, urokinase, Platelet Factor 4 ("PF4"), alpha-fetoprotein, alpha- 1-antitrypsin, C-l esterase inhibitor, decorin, alpha interferon, beta interferon, ferritin, prolactin, CFTR, blood Factor X, blood Factor VIII, as well as erythropoietin.
- a fusion protein partner including: antithrombin III, truncated ATIII, lactoferrin, urokinase, Platelet Factor 4 ("PF4"), alpha-fetoprotein, alpha- 1-antitrypsin, C-l esterase inhibitor, decorin, alpha interferon, beta interferon, ferritin, prolactin, CFTR, blood Factor X
- the fusion partner may be, and for preference usually will be, a natural protein or physiologically active fragment thereof, but it does not have to be. Proteins which themselves can be produced in high yields in milk, such as alpha- 1-antitrypsin, are likely to be useful fusion partners in the invention.
- a list of desirable of proteins includes: antithrombin III, truncated ATIII, lactoferrin, urokinase, Platelet Factor 4 ("PF4"), alpha-fetoprotein, alpha- 1-antitrypsin, C-l esterase inhibitor, decorin, alpha interferon, beta interferon, ferritin, prolactin, CFTR, blood Factor X, blood Factor VIII, as well as erythropoietin.
- the fusion partner may additionally be a protein which is naturally produced in milk, as it is reasonable to assume that a protein which is normally secreted into milk, and which can be produced at high levels, will continue to be so secreted and produced after another functional polypeptide has been fused to its carboxy terminus.
- a particularly prefened fusion partner for the production of a fusion protein of interest in milk is human alpha-fetoprotein.
- IRES linker sequence variant 1 SEQ. ID. 24.
- Any C-terminal extension to the first fusion partner such as the human alpha-fetoprotein extension discussed above, may also be regarded as part of the linker.
- bi-functional fusion proteins are produced in the milk of transgenic animals.
- the human alpha-fetoprotein coding sequences can be obtained by screening libraries of genomic material or reverse- translated messenger RNA derived from the animal of choice (such as cattle or mice). These sequences along with the desired polypeptide sequence of the fusion partner protein are then cloned into an appropriate plasmid vector and amplified in a suitable host organism, usually E. coli.
- the DNA sequence encoding the peptide of choice can then be constructed, for example, by polymerase chain reaction amplification of a mixture of overlapping annealed oligonucleotides.
- the DNA construct After amplification of the vector, the DNA construct would be excised with the appropriate 5' and 3' control sequences, purified away from the remains of the vector and used to produce transgenic animals that have integrated into their genome the desired bi-functional fusion protein. Conversely, with some vectors, such as yeast artificial chromosomes (YACs), it is not necessary to remove the assembled construct from the vector; in such cases the amplified vector may be used directly to make transgenic animals.
- YACs yeast artificial chromosomes
- bi-functional refers to the presence of a first polypeptide encoded by enough of a protein sequence nucleic acid sequence to retain its biological activity, this first polypeptide is then joined to a the coding sequence for a second polypeptide also containing enough of a polypeptide sequence of a protein to retain its physiological activity.
- the coding sequence being operatively linked to a control sequence which enables the coding sequence to be expressed in the milk of a transgenic non-human placental mammal.
- a DNA sequence which is suitable for directing production to the milk of fransgenic animals carries a 5 '-promoter region derived from a naturally-derived milk protein and is consequently under the control of hormonal and tissue-specific factors.
- the promoter so utilized can be followed by a DNA sequence directing the production of a protein leader sequence which would direct the secretion of the fusion protein across the mammary epithelium into the milk.
- a suitable 3'-sequence preferably also derived from a naturally secreted milk protein, and may be added to improve stability of mRNA.
- suitable control sequences for the production of proteins in the milk of transgenic animals are those from the caprine beta casein promoter.
- Prefened fusion proteins of the invention will be illustrated by the following examples.
- the prefened embodiment of this invention is a fusion protein made from a human alpha-fetoprotein polypeptide joined via a single methionine residue at its carboxy tenninus to an ⁇ interferon polypeptide (IFN- ⁇ ).
- IFN- ⁇ ⁇ interferon polypeptide
- the IFN- ⁇ polypeptide would carry an extra glycine at the carboxy terminus to act as a substrate for the alpha-amidating enzyme.
- the DNA sequence encoding this construct would cany the 5'-beta-casein promoter region, the entire human alpha-fetoprotein coding sequence with all of the coding exons, a linker and then the human IFN- ⁇ coding sequence.
- a fusion protein has the same fusion partners as that provided above but uses a different linker sequence. This requires the fusion protein to cany the amino acid linker sequence between the carboxy terminus of the human alpha-fetoprotein and the IFN- ⁇ . [0080] This would have to be produced by making appropriate changes in the DNA coding region.
- a fusion protein may be prepared as described above but under the control of the human or bovine 5'- and 3 '-control sequences either from beta- lactoglobulin or from any other suitable promoter involved in controlling the expression of milk proteins.
- the fusion proteins of the invention provide for use of a physiologically active alpha-fetoprotein polypeptide as a first domain linked to various second polypeptide fusion partners.
- This invention contemplates and includes all interferon's native, natural, modified, or recombinant DNA interferon-like proteins as the potential fusion partner of the alpha-fetoprotein domain.
- interferon's and others known proteins are in the art or to be known are within the contemplation of the invention.
- the present invention is principally concerned with various modified fusion proteins or polypeptides of alpha and beta interferon's fused to an alpha-fetoprotein domain. Glycosylated interferon's have been reported to be obtained by expressing the proteins in animal cells or in yeast.
- the selection of the position of the molecule best suited for a modification depends on the particular protein.
- recognition of desirable sequences that retain their native physiological activity can be introduced at any point in a naturally occurring protein sequence providing such introduced sequences do not adversely affect biological activity where such activity is desired. It is only necessary in accordance with the invention that there be incorporated that much of the amino acid consensus sequence that will contain or be the site for the desired biological activity.
- the following describes illustrative, but not limiting, specific embodiments.
- Antithrombin III is a single chain glycoprotein involved in the coagulation process. It is synthesized primarily in the liver with a signal peptide of 32 amino acids necessary for its intracellular transport through the endoplasmic reticulum; the peptide is then cleaved prior to secretion. Mourey et al., Biociar iE 72:599-608 (1990). [0085] ATIII is a member of the serpin family of proteins and functions as an inhibitor of thrombin and other enzymes involved in the clotting cascade.
- S-ATIII the active native intact form of ATIII is designated the S (stressed) form (S- ATIII).
- S-ATIII forms a tight binding complex with thrombin (markedly enhanced by the presence of heparin) and other enzymes (not all serpins have heparin affinity).
- S-ATIII can be cleaved to the relaxed (R)-conformation (R-ATIII) by a variety of enzymes, including thrombin.
- ATIII can be derived from any organism which produces the protein in nature. In a particular embodiment the organism is bovine or human. The amino acid sequence of bovine ATIII is available under GenBank Accession No. 1168462, and the amino acid sequence of human ATIII is available under GenBank Accession No.
- ATIII or its biological equivalents may also be produced by the use of an enzyme (e.g. elastase) in vivo.
- an enzyme e.g. elastase
- an enzyme maybe used in vivo, with or without plasma or native ATIII to serve as an additional substrate, to produce a fragment, conformation, biological equivalent, or derivative of ATIII that inhibits endothelial cell proliferation, angiogenesis and/or tumor growth. It has been determined that certain conformations of ATIII reduce angiogenesis, endothelial cell proliferation, and tumor growth.
- endothelial cell proliferation also includes endothelial cell migration and tube fonnation.
- ATIII and/or a fragment, conformation, biological equivalent, or derivative can be made or isolated by numerous methods known in the art, including, but not limited to, purification, fransgenic and recombinant methods.
- the insertion of the nucleotide sequence is preferably made at a site in the nucleotide sequence encoding IFN- ⁇ so as to minimize an undesirable effect on the biological activity of the resultant recombinant protein, when such biological activity is critical.
- the transcriptional promoters useful in practicing the present invention are those promoters that are preferentially activated in mammary epithelial cells, including promoters that control the genes encoding milk proteins such as caseins, beta- lacto globulin (Clark et al., (1989) BIO/TECHNOLOGY 1: 487-492), whey acid protein (Gorton et al. (1987) BIO/TECHNOLOGY 5: 1183-1187), and lactalbumin (Soulier et al., (1992) FEBS LETTS. 297: 13).
- Casein promoters may be derived from the alpha, beta, gamma or kappa casein genes of any mammalian species; a prefened promoter is derived from the goat beta casein gene (DiTullio, (1992) Bio/TECHNOLOGY 10:74-77).
- the milk-specific protein promoter or the promoters that are specifically activated in mammary tissue may be derived from either cDNA or genomic sequences. Preferably, they are genomic in origin. [0090] DNA sequence information is available for all of the mammary gland specific genes listed above, in at least one, and often several organisms. See, e.g., Richards et al., J. BlOL. CHEM.
- the signal sequences that are useful in accordance with this invention are milk-specific signal sequences or other signal sequences which result in the secretion of eukaryotic or prokaryotic proteins.
- the signal sequence is selected from milk-specific signal sequences, i.e., it is from a gene which encodes a product secreted into milk.
- the milk-specific signal sequence is related to the milk-specific promoter used in the expression system of this invention.
- the size of the signal sequence is not critical for this invention. All that is required is that the sequence be of a sufficient size to effect secretion of the desired recombinant protein, e.g., in the mammary tissue.
- signal sequences from genes coding for caseins e.g., alpha, beta, gamma or kappa caseins, beta lactoglobulin, whey acid protein, and lactalbumin are useful in the present invention.
- the prefened signal sequence is the goat ⁇ -casein signal sequence.
- Signal sequences from other secreted proteins e.g., proteins secreted by liver cells, kidney cell, or pancreatic cells can also be used.
- the efficacy with which a non-secreted protein is secreted can be enhanced by inclusion in the protein to be secreted all or part of the coding sequence of a protein which is normally secreted.
- the entire sequence of the protein which is normally secreted is not included in the sequence of the protein but rather only a portion of the amino terminal end of the protein which is normally secreted.
- a protein which is not normally secreted is fused (usually at its amino terminal end) to an amino terminal portion of a protein which is normally secreted.
- the protein which is normally secreted is a protein which is normally secreted in milk.
- Such proteins include proteins secreted by mammary epithelial cells, milk proteins such as caseins, beta lacto globulin, whey acid protein, and lactalbumin.
- Casein proteins include alpha, beta, gamma or kappa casein genes of any mammalian species.
- a prefened protein is beta casein, e.g., a goat beta casein.
- the sequences which encode the secreted protein can be derived from either cDNA or genomic sequences. Preferably, they are genomic in origin, and include one or more infrons.
- the expression system or construct, described herein, can also include a 3' unfranslated region downstream of the DNA sequence coding for the non-secreted protein. This region apparently stabilizes the RNA transcript of the expression system and thus increases the yield of desired protein from the expression system.
- 3' untranslated regions useful in the constructs of this invention are sequences that provide a poly A signal. Such sequences may be derived, e.g., from the SV40 small t antigen, the casein 3' untranslated region or other 3' unfranslated sequences well known in the art.
- the 3' untranslated region is derived from a milk specific protein.
- the expression system or construct includes a 5' untranslated region between the promoter and the DNA sequence encoding the signal sequence.
- Such untranslated regions can be from the same control region from which promoter is taken or can be from a different gene, e.g., they may be derived from other synthetic, semi-synthetic or natural sources. Again their specific length is not critical, however, they appear to be useful in improving the level of expression.
- the construct can also include about 10%, 20%, 30%, or more of the N- terminal coding region of the gene preferentially expressed in mammary epithelial cells.
- the N-terminal coding region can conespond to the promoter used, e.g., a goat ⁇ -casein N-terminal coding region.
- the above-described expression systems may be prepared using methods well known in the art. For example, various ligation techniques employing conventional linkers, restriction sites etc. may be used to good effect.
- the expression systems of this invention are prepared as part of larger plasmids. Such preparation allows the cloning and selection of the conect constructions in an efficient manner as is well known in the art.
- the expression systems of this invention are located between convenient restriction sites on the plasmid so that they can be easily isolated from the remaining plasmid sequences for incorporation into the desired mammal.
- Prior art methods often include making a construct and testing it for the ability to produce a product in cultured cells prior to placing the construct in a transgenic animal.
- the inventors have found that such a protocol may not be of predictive value in determining if a normally non-secreted protein can be secreted, e.g., in the milk of a transgenic animal. Therefore, it may be desirable to test constructs directly in transgenic animals, e.g., transgenic mice, as some constructs which fail to be secreted in CHO cells are secreted into the milk of transgenic animals.
- the DNA constructs of the invention are introduced into the germ line of a mammal.
- one or several copies of the construct may be incorporated into the genome of a mammalian embryo by standard fransgenic techniques known in the art.
- Any non-human mammal can be usefully employed in this invention. Mammals are defined herein as all animals, excluding humans, which have mammary glands and produce milk. Preferably, mammals that produce large volumes of milk and have long lactating periods are prefened. Prefened mammals are cows, sheep, goats, mice, oxen, camels and pigs.
- each of these mammals may not be as effective as the others with respect to any given expression sequence of this invention.
- a particular milk-specific promoter or signal sequence may be more effective in one mammal than in others.
- one of skill in the art may easily make such choices by following the teachings of this invention.
- the litters of transgenic mammals may be assayed after birth for the incorporation of the construct into the genome of the offspring.
- this assay is accomplished by hybridizing a probe conesponding to the DNA sequence coding for the desired recombinant protein product or a segment thereof onto chromosomal material from the progeny.
- Those mammalian progeny found to contain at least one copy of the construct in their genome are grown to maturity.
- Transgenic females may be tested for protein secretion into milk, using any of the assay techniques that are standard in the art (e.g., Western blots or enzymatic assays).
- modified interferon's can be produced from vertebrate cell cultures, for instance, a COS-7 line of monkey kidney fibroblasts can be used as the host for the production of the modified interferon's with appropriate expression vectors.
- Vectors useful in the invention to replicate in a transformed host cell have a DNA segment containing a functional origin of replication (replicon). Plasmids and phage DNA by their very nature contain replicons facilitating replication in a host cell. The vector will have a DNA segment which conveys to a transformable host cell a property useful for selection of transformed cells from non-transformed cells. Any of a wide range of properties can be used for selection purposes. One of the most commonly used properties is antibiotic resistance, e.g., neomycin resistance or tetracycline resistance.
- the AFP fusion protein of the invention may be purified from the biological fluid of a transgenic organism using standard protein purification techniques, such as affinity chromatography (see, e.g., Ausubel et al., CURRENT PROTOCOLS IN
- the AFP-fiision protein can, if desired, be further purified by e.g., by high performance liquid chromatography (HPLC; e.g., see Fisher, LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, eds. Work and Burdon, Elsevier, 1980), and/or tangential flow filtration.
- HPLC high performance liquid chromatography
- the AFP fusion protein is at least 80% pure, preferably 90% pure, more preferably 95% pure, and most preferably 99% pure.
- Useful promoters for the expression of AFP in mammary tissue include promoters that naturally drive the expression of mammary-specific polypeptides, such as milk proteins, although any promoter that permits secretion of AFP into milk can be used. These include, e.g., promoters that naturally direct expression of whey acidic protein (WAP), alpha SI -casein, alpha S2-casein, beta- casein, kappa-casein, beta-lactoglobulin, alpha-lactalbumin (see, e.g., Drohan et al., U.S. Patent No. 5,589,604; Meade et al., U.S. Patent No.
- WAP whey acidic protein
- Whey acidic protein (WAP; Genbank Accession No. XOl 153), the major whey protein in rodents, is expressed at high levels exclusively in the mammary gland during late pregnancy and lactation (Hobbs et al., J. BIOL. CHEM. 257:3598-3605, 1982).
- Whey acidic protein (WAP; Genbank Accession No. XOl 153)
- XOl 153 the major whey protein in rodents
- Hobbs et al. J. BIOL. CHEM. 257:3598-3605, 1982.
- desired mammary gland-specific promoters see, e.g., Richards et al., J. BlOL. CHEM.
- Mammary-gland specific regulatory sequences from different organisms can be obtained by screening libraries from such organisms using known cognate nucleotide sequences, or antibodies to cognate proteins as probes.
- Useful signal sequences for expression and secretion of AFP into milk are milk-specific signal sequences.
- the signal sequence is selected from milk-specific signal sequences, i.e., from a gene which encodes a product secreted into milk.
- the milk-specific signal sequence is related to a milk-specific promoter described above.
- the size of the signal sequence is not critical for this invention. All that is required is that the sequence be of a sufficient size to effect secretion of AFP, e.g., in the mammary tissue.
- signal sequences from genes coding for caseins e.g., alpha, beta, gamma, or kappa caseins, beta lactoglobulin, whey acidic protein, and lactalbumin are useful in the present invention.
- Signal sequences from other secreted proteins e.g., proteins secreted by liver cells, kidney cell, or pancreatic cells can also be used.
- Useful promoters for the expression of a recombinant polypeptide transgene in urinary tissue are the uroplakin and uromodulin promoters (Ken et al., NAT. BIOTECHNOL. 16:75-79, 1998; Zbikowska, et al., BIOCHEM. J.
- a useful promoter for the expression and secretion of AFP into blood by blood-producing or serum-producing cells is the albumin promoter (see, e.g., Shen et al., DNA 8:101-108, 1989; Tan et al., DEV. BIOL. 146:24- 37, 1991; McGrane et al, TIBS 17:40-44, 1992; Jones et al., J. BlOL. CHEM.
- any promoter that permits secretion of the transgene product into blood may be used.
- the native alpha-fetoprotein promoter can also be used (see, e.g., Genbank Accession Nos.: AB053574; AB053573; AB053572; AB053571; AB053570; and AB053569).
- Useful promoters for the expression of AFP in semen are described in U.S. Patent No. 6,201,167.
- Useful avian-specific promoters are the ovalbumin I promoter and the apo-B promoter. Other avian-specific promoters are known in the art.
- the ovalbumin promoter can be used to direct expression of AFP that is then deposited in the egg white of the egg.
- the apo-B promoter can also be used to direct expression of a recombinant polypeptide in the liver, where it will eventually be deposited into the egg yolk.
- Avian eggs are an optimal vehicle for expressing large quantities of recombinant polypeptides for the following reasons: (1) a large amount of protein is ( packed into each egg, (2) eggs are easy to collect non-invasively and can be stored for extended periods of time, and (3) eggs are sterile and, unlike milk, do not contain bacterial contaminants. Specifically, for each egg, a bird can produce three grams of albumin in the oviduct, of which greater than 50% is ovalbumin.
- AFP protein kinase
- Other promoters that are useful in the methods of the invention include inducible promoters. Generally, recombinant proteins are expressed in a constitutive manner in most eukaryotic expression systems. The addition of inducible promoters or enhancer elements provides temporal or spatial control over expression of AFP, and provides an alternative mechanism of expression.
- Inducible promoters include heat shock protein, metallothionien, and MMTV-LTR, while inducible enhancer elements include those for ecdysone, muristerone A, and tetracycline/ doxycycline.
- Tet-On and Tet-Off Gene Expression Systems (Clontech) is one example of an inducible system that is useful in the methods of the invention. This system uses a tetracycline (Tc) responsive element to maintain AFP expression in either an on (constitutively off, induced with Tc) or off (constitutively on, repressed with Tc or doxycycline) mode.
- Tc tetracycline
- Selectable markers can also be incorporated into the AFP transgene for easy identification of cells that have been transformed.
- Selectable markers generally fall into two functional categories: recessive and dominant.
- the recessive markers are usually genes that encode products that are not produced in the host cells (cells that lack the "marker" product or function).
- Marker genes for thymidine kinase (TK), dihydrofolate reductase (DHFR), adenine phosphoribosyl transferase (APRT), and hypoxanthine-guanine phosphoribosyl transferase (HGPRT) are in this category.
- Dominant markers include genes that encode products that confer resistance to growth-suppressing compounds (antibiotics, drugs) and/or permit growth of the host cells in metabohcally restrictive environments. Commonly used markers within this category include a mutant DHFR gene that confers resistance to methotrexate; the gpt gene for xanthine-guanine phosphoribosyl transferase, which permits host cell growth in mycophenolic acid/xanthine containing media; and the neo gene for aminoglycoside 3'-phosphotransferase, which can confer resistance to G418, gentamycin, kanamycin, and neomycin.
- Nucleic Acid Vectors [00114] In certain embodiments the invention concerns vectors, or recombinant expression vectors, comprising any of the nucleic acid molecules described herein. Vectors are used herein either to amplify DNA or RNA encoding fusion proteins and/or to express DNA which encodes SSTR-fusion proteins. Vectors include, but are not limited to, plasmids, phages, cosmids, episomes, viral particles or viruses, and integratable DNA fragments (i.e., fragments integratable into the host genome by homologous recombination).
- Viral particles include, but are not limited to, adenoviruses, baculoviruses, parvoviruses, herpesviruses, poxviruses, adeno-associated viruses, Semliki Forest viruses, vaccinia viruses, retroviruses, microparticles and naked DNA.
- expression may be targeted to a particular cell type or cell population by a targeting ligand.
- Expression vectors include, but are not limited to, pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech).
- Expression constructs include, but are not limited to, pSPORTTM vectors, pGEMTM vectors (Promega), pPROEXvectorsTM (LTI, Bethesda, Md.), BluescriptTM vectors (Stratagene), pQE. TM vectors (Qiagen), pSE420TM (Invitrogen), and pYES2TM (Invitrogen).
- Expression constructs may comprise a fusion protein encoding polynucleotides operatively linked to an endogenous or exogenous expression control DNA sequence and a transcription terminator. Because of limited space for nucleic acid insertion in many vectors it may be desirable to insert smaller reporters or reporter fusion constructs.
- Expression control DNA sequences include promoters, enhancers, operators, and regulatory element binding sites generally, and are typically selected based on the expression systems in which the expression construct is to be utilized. [00115] Promoter and enhancer sequences are generally selected for the ability to increase gene expression, while operator sequences are generally selected for the ability to regulate gene expression.
- Expression constructs of the invention may also include sequences encoding one or more selectable markers that permit identification of host cells bearing the construct. Expression constructs may also include sequences that facilitate homologous recombination in a host cell. In various embodiments constructs may also include sequences necessary for replication in a host cell.
- tissue-specific promoters are listed herein (Pearse and Takor, 1979; Nylen and Becker, 1995). Although not a complete list, these promoters are exemplary of the types of promoters and enhancers that may be used in certain embodiments of the invention. Additional promoters, useful in the present invention, will be readily known to those of skill in the art.
- Inducible promoters include but are not limited to MT II, MMTV (mouse mammary tumor virus), c-jun, Collagenase, Sfromelysin, Murine MX Gene, GRP78 Gene, ⁇ -2-Macroglobulin, Viinentin, MHC Class I Gene H-2 kB, HSP70, Proliferin, Tumor Necrosis Factor and Thyroid Stimulating Hormone- ⁇ .
- Cell or tissue specific expression can be achieved by using cell-specific enhancers and/or promoters. (See generally, Huber et al., ADV. DRUG DELIVERY REVIEWS 17:279-292, 1995).
- Expression constructs may be utilized for production of an encoded protein, but may also be utilized simply to amplify an SSTR-fusion protein encoding polynucleotide sequence.
- the vector is an expression vector wherein the polynucleotide is operatively linked to a polynucleotide comprising an expression control sequence.
- autonomously replicating recombinant expression constructs such as plasmid and viral DNA vectors incorporating polynucleotides.
- Expression vectors may be replicable DNA constructs in which a DNA sequence encoding SSTR-fusion protein is operably linked or connected to suitable control sequences capable of effecting the expression of an SSTR-fusion protein in a suitable host.
- DNA regions are operably linked or connected when they are functionally related to each other.
- a promoter is operably linked or connected to a coding sequence if it controls the transcription of the sequence.
- Amplification vectors do not require expression control domains, but rather need only the ability to replicate in a host, usually confened by an origin of replication, and a selection gene to facilitate recognition of fransformants.
- the need for control sequences in the expression vector will vary depending upon the host selected and the transformation method chosen.
- control sequences include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding and sequences that controls the termination of transcription and translation.
- vectors may contain a promoter that is recognized by the host organism.
- the promoter sequences may be prokaryotic, eukaryotic, synthetic or viral.
- suitable prokaryotic sequences include the promoters of bacteriophage lambda (THE BACTERIOPHAGE LAMBDA, Hershey, A. D., Ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1973); LAMBDA II, Hendrix, R. W., Ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1980); and, Benoist et al., The trp, recA, heat shock, and lacZ promoters ofE.
- Additional promoters include, but are not limited to, mouse mammary tumor virus, long terminal repeat of human immunodeficiency virus, maloney virus, cytomegalovirus immediate early promoter, Epstein Ban vims, Rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine, and human metalothionein.
- Additional regulatory sequences may also be included in vectors. Examples of suitable regulatory sequences are represented by the Shine-Dalgarno of the replicase gene of the phage MS-2 and ⁇ of the gene ell of bacteriophage lambda.
- suitable expression vectors can include an appropriate marker that allows the screening of the transformed host cells.
- the transformation of the selected host is carried out using any one of the various techniques well known to the expert in the art and described in Sambrook et al., supra.
- An origin of replication may also be provided either by construction of the vector to include an exogenous origin or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter may be sufficient.
- nucleotide sequences encoding reporter protein fusions such as
- SSTR2-fusion proteins may be recombined with vector DNA in accordance with conventional techniques, including blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases. Techniques for such manipulation are disclosed by Sambrook et al., supra and are well known in the art. Methods for construction of mammalian expression vectors are disclosed in, for example, Okayama et al., MOL. CELL. BIOL.,
- the transgene construct preferably includes a leader sequence downstream from the promoter.
- the leader sequence is a nucleic acid sequence that encodes a protein secretory signal, and, when operably linked to a downstream nucleic acid molecule encoding the AFP-fusion protein of the invention, and directs AFP- fusion secretion.
- the leader sequence may be obtained from the same gene as the promoter used to direct transcription of the nucleic acid molecule encoding AFP (for example, a gene that encodes a milk-specific protein).
- a leader sequence encoding the native human AFP protein secretory signal (amino acids 1-19 of Genbank Accession No. V01514) may be employed.
- compositions used are in the dosage form of solid, semi-solid or liquid such as, e.g., tablets, pills, powders, capsules, gels, ointments, liquids, suspensions, or the like.
- compositions are administered in unit dosage forms suitable for single administration of precise dosage amounts.
- the compositions may also include, depending on the formulation desired, pharmaceutically acceptable carriers or diluents, which are defined as aqueous-based vehicles commonly used to formulate pharmaceutical compositions for animal or human administration.
- the diluent is selected so as not to affect the biological activity of the human alpha-fetoprotein.
- examples of such diluents are distilled water, physiological saline, Ringer's solution, dextrose solution, and Hank's solution. The same diluents may be used to reconstitute lyophilized human alpha-fetoprotein.
- the pharmaceutical composition may also include other medicinal agents, pharmaceutical agents, carriers, adjuvants, nontoxic, non-therapeutic, non-immunogenic stabilizers, etc. Effective amounts of such diluent or carrier will be amounts which are effective to obtain a pharmaceutically acceptable formulation in terms of solubility of components, biological activity, etc.
- compositions herein may be administered to human patients via oral, parenteral or topical administrations and otherwise systemic forms for anti- melanoma and anti-breast cancer treatment.
- Fusion Protein Multiple Functional Domains.
- bi-functional fusion proteins are contemplated that have unique dual therapeutic effects on Myasthenia Gravis, Rheumatoid Arthritis, Osteoporosis, Cancer, topical applications, and Multiple Sclerosis. Other areas of effectiveness include antiviral activity, immunoregulatory activity and anti-angiogenic activity (cleaved ATIII fusion-AFP protein).
- Conservative variants according to the invention generally conserve the overall molecular structure of the protein domains.
- amino acid substitutions i.e. "conservative substitutions” may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
- nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine;
- polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine;
- positively charged (basic) amino acids include arginine, lysine, and histidine;
- negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions typically may be made within groups (a)-(d).
- glycine and proline may be substituted for one another based on their ability to disrupt .alpha. -helices.
- certain amino acids such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine are more commonly found in a-helices, while valine, isoleucine, phenylalanine, tyrosine, tryptophan and threonine are more commonly found in .beta. -pleated sheets.
- Glycine, serine, aspartic acid, asparagine, and proline are commonly found in turns.
- a bi-functional protein contemplated by this invention is one that contains each of the previously mentioned domains, wherein upon such fusing, both domains substantially retain their associated characteristics and may have a synergistic effect on certain therapeutic applications such as myasthenia gravis or rheumatoid arthritis.
- the domains also may be fused by conventional chemical means, using multifunctional cross-linkers, for example.
- fusion proteins either domain may be placed C-terminal or N-terminal to the other. Suitable methods for creating the fusion protein should be ones that do not substantially change the biological activity of either of the two polypeptides of the desired fusion protein.
- the present invention is not limited to any particular method of producing the desired fusion protein contemplated herein. According to the contemplated recombinant methods of production, however, the invention provides recombinant DNA constructs comprising one or more of the nucleotide sequences of the domains described in the present invention.
- the recombinant constructs of the present invention comprise a vector, such as a plasmid or viral vector, into which a DNA or DNA fragment, typically bearing an open reading frame, is inserted, in either orientation.
- the invention further contemplates cells containing these vectors.
- Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter.
- the vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and, if desirable, to provide amplification within the host.
- Suitable prokaryotic hosts for transformation include E. coli., Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may, also be employed as a matter of choice. In a prefened embodiment, the prokaryotic host is E. coli.
- Bacterial vectors may be, for example, bacteriophage-, plasmid- or cosmid-based. These vectors can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids typically containing elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, GEM 1 (Promega Biotec, Madison, Wis., USA), pBs,
- a prefened vector according to the invention is THE Pt7I expression vector.
- Bacterial promoters include lac, T3, T7, lambda PR or PL, trp, and ara. T7 is a prefened bacterial promoter.
- the selected promoter is de-repressed/induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.
- appropriate means e.g., temperature shift or chemical induction
- Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.
- Eukaryotic Expression Various mammalian cell culture systems can also be employed to express recombinant protein.
- mammalian expression systems include selected mouse L cells, such as thymidine kinase-negative (TK) and adenine phosphoribosul transferase-negative (APRT) cells.
- TK thymidine kinase-negative
- APRT adenine phosphoribosul transferase-negative
- Other examples include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines.
- yeasts there may be mentioned yeasts of the genus Saccharomyces, Kluyveromyces, Pichia, Schwanniomyces, or Hansenula.
- yeasts capable of being used in the present invention there may be mentioned more particularly Aspergillus ssp, or Trichoderma ssp.
- Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking non-transcribed sequences.
- DNA sequences derived from the S V40 viral genome may be used to provide the required non-transcribed genetic elements.
- Mammalian promoters include beta-casein, beta-lactoglobulin, whey acid promoter others include: HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-1.
- Exemplary mammalian vectors include pWLneo, pSV2cat, pOG44, pXTl, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia).
- the mammalian expression vector is pUCIG- MET.
- Selectable markers include CAT (chloramphenicol transferase).
- mRNAs messenger RNAs
- cDNA complementary DNA
- nucleotide sequences may also be subsequently modified, for example by the techniques of genetic engineering, in order to obtain derivatives or variants of the said sequences.
- FISH Fluorescence In situ Hybridization
- compositions [00141 ]
- the proteins of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the inventive molecules, or their functional derivatives, are combined in admixture with a pharmaceutically acceptable carrier vehicle.
- Suitable vehicles and their formulation, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in order to form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of one or more of the proteins of the present invention, together with a suitable amount of carrier vehicle.
- Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.
- the bi-functional molecules and their physiologically acceptable salts and solvate may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.
- the pharmaceutical compositions may take the fonn of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpynolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
- binding agents e.g., pregelatinised maize starch, polyvinylpynolidone or hydroxypropyl methylcellulose
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they maybe presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
- suspending agents e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats
- emulsifying agents e.g., lecithin or acacia
- non-aqueous vehicles e.g., almond oil, oily esters, ethyl
- preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.
- the bi-functional molecules for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethan- e, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of, e.g. gelatin for use in an inhaler or insufflator maybe formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- the bi-functional fusion proteins of the invention may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative.
- compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- the bi-functional molecules may also be formulated as a depot preparation.
- Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- suitable polymeric or hydrophobic materials for example as an emulsion in an acceptable oil
- ion exchange resins for example as an emulsion in an acceptable oil
- sparingly soluble derivatives for example, as a sparingly soluble salt.
- the compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack may for example comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- Some fusion protein compositions of the cunent invention may be therapeutically useful in cancer treatment.
- chemotherapeutic agents include alkylating agents, antimetabolites, various natural products (e.g., vinca alkaloids, epipodophyllotoxins, antibiotics, and amino acid- depleting enzymes), hormones and hormone antagonists.
- Specific classes of agents include nitrogen mustards, alkyl sulfonates, nitrosoureas, triazenes, folic acid analogues, pyrimidine analogues, purine analogs, platinum complexes, adrenocortical suppressants, adrenocorticosteroids, progestins, estrogens, antiestrogens and androgens.
- Some exemplary compounds include cyclophosphamide, chlorambucil, methofrexate, fluorouracil, cytarabine, thioguanine, vinblastine, vincristine, doxorubicin, daunorubicin, mitomycin, cisplatin, hydroxyurea, prednisone, hydroxyprogesterone caproate, medroxyprogesterone, megestrol acetate, diethyl stilbestrol, ethinyl estradiol, tamoxifen, testosterone propionate and fluoxymesterone.
- tamoxifen is prefened.
- the inventive therapeutic methods according to the invention generally utilize the bi-functional proteins identified above.
- the domains of the fusion proteins share the ability to specifically target a specific tissue and/or augment an immune response to targeted tissue.
- a typical method accordingly, involves binding a receptor of a targeted cell to the receptor-antagonizing domain of the fusion protein and/or stimulating a T-cell dependent immune response.
- Therapeutic methods involve administering to a subject in need of treatment a therapeutically effective amount of a fusion protein.
- “Therapeutically effective” is employed here to denote the amount of fusion proteins that are of sufficient quantity to inhibit or reverse a disease condition (e.g., reduce or inhibit cancer growth).
- the patient may be a human or non-human animal.
- a patient typically will be in need of treatment when suffering from a cancer characterized by increased levels of receptors that promote cancer maintenance or proliferation.
- Administration during in vtvotreatment may be by any number of routes, including parenteral and oral, but preferably parenteral.
- Intracapsular, intravenous, infrathecal, and intraperitoneal routes of administration may be employed, generally intravenous is prefened. The skilled artisan will recognize that the route of administration will vary depending on the disorder to be treated.
- a therapeutically effective amount specifically will depend on such factors as toxicity and efficacy of the medicament. Toxicity may be determined using methods well known in the art and found in the foregoing references. Efficacy may be determined utilizing the same guidance in conjunction with the methods described below in the Examples. A pharmaceutically effective amount, therefore, is an amount that is deemed by the clinician to be toxicologically tolerable, yet efficacious. Efficacy, for example, can be measured by the induction or substantial induction of T lymphocyte cytotoxicity at the targeted tissue or a decrease in mass of the targeted tissue. Suitable dosages can be from about 1 mg/kg to 10 mg/kg.
- the present invention also provides cell-based assay systems that can be used to compare the biological activities of each of the polypeptide domains of a given fusion protein of the invention. To this end, a cell proliferation assay is used to ensure that the fused domains of the fusion protein each retain a biological function similar to the native protein when it is not fused (i.e. not part of a fusion protein).
- the biological activity of the fusion protein will be determined by introducing the protein to two separate types of cell lines in vitro: each cell line determining the activity of a specific domain.
- a cell line that is a reliable indicator of the biological activities of a first polypeptide domain should be used to test the effects of that domain, while a cell line capable of indicating the biological effect of a second polypeptide domain should be used to monitor the activity of the other domain. This will also help determine synergistic effects and additive effects of the two functional fusion protein domains.
- the following examples are illustrative and should not be considered limiting
- the AFP-fusion transgene construct may be carried within a circular plasmid, a cosmid vector, or other vector, such as a vector derived from a virus.
- the vector may contain additional sequences that facilitate its propagation in prokaryotic and eukaryotic cells, for example, drug-selectable markers (e.g., for ampicillin resistance in E. coli, or G-418 resistance in mammalian cells) and origins of replication (e.g., colEl for replication in prokaryotic cells, and oriP for replication in mammalian cells).
- drug-selectable markers e.g., for ampicillin resistance in E. coli, or G-418 resistance in mammalian cells
- origins of replication e.g., colEl for replication in prokaryotic cells, and oriP for replication in mammalian cells.
- Example 3 Purifying the Fusion Protein
- steps include: collecting the milk from a fransgenic animal or removing the cells from culture via centrifugation, followed by precipitation, tangential flow filtration, and chromatography methodologies, such as low pressure SEC and preparative RP-HPLC chromatography. These steps are followed by: buffer exchange, depyrogenation, and lyophilization.
- Cibelli JB (1998) et al, Cloned Transgenic Calves Produced From Nonquiescent Fetal Fibroblasts. SCIENCE; 280: 1256-1258.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006525523A JP2007503838A (en) | 2003-09-05 | 2004-09-03 | Method for producing fusion protein in milk of transgenic animals |
EP04783398A EP1670931A2 (en) | 2003-09-05 | 2004-09-03 | Method for the production of fusion proteins in transgenic mammal milk |
CA002537273A CA2537273A1 (en) | 2003-09-05 | 2004-09-03 | Method for the production of fusion proteins in transgenic mammal milk |
AU2004271200A AU2004271200A1 (en) | 2003-09-05 | 2004-09-03 | Method for the production of fusion proteins in transgenic mammal milk |
IL174011A IL174011A0 (en) | 2003-09-05 | 2006-02-28 | Method for the production of fusion proteins in transgenic mammal milk |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50091003P | 2003-09-05 | 2003-09-05 | |
US60/500,910 | 2003-09-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005024044A2 true WO2005024044A2 (en) | 2005-03-17 |
WO2005024044A3 WO2005024044A3 (en) | 2005-06-02 |
Family
ID=34273009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/029128 WO2005024044A2 (en) | 2003-09-05 | 2004-09-03 | Method for the production of fusion proteins in transgenic mammal milk |
Country Status (8)
Country | Link |
---|---|
US (2) | US7550263B2 (en) |
EP (1) | EP1670931A2 (en) |
JP (1) | JP2007503838A (en) |
CN (1) | CN1871252A (en) |
AU (1) | AU2004271200A1 (en) |
CA (1) | CA2537273A1 (en) |
IL (1) | IL174011A0 (en) |
WO (1) | WO2005024044A2 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
WO2007126546A1 (en) * | 2006-03-30 | 2007-11-08 | Cogenesys, Inc. | Fusion proteins comprising alpha fetoprotein |
WO2007144173A1 (en) | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
WO2008098720A1 (en) * | 2007-02-12 | 2008-08-21 | Csl Behring Gmbh | Therapeutic application of kazal-type serine protease inhibitors |
EP2004844A2 (en) * | 2006-03-29 | 2008-12-24 | Merrimack Pharmaceuticals, Inc. | Coadministration of alpha-fetoprotein and a disease modifying anti-rheumatic drug for treating inflammatory arthritic disease |
WO2009156137A1 (en) * | 2008-06-24 | 2009-12-30 | Csl Behring Gmbh | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
EP2256135A1 (en) | 2006-06-14 | 2010-12-01 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
EP2371857A1 (en) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
WO2012120128A1 (en) | 2011-03-09 | 2012-09-13 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
WO2013113774A1 (en) | 2012-01-31 | 2013-08-08 | Csl Behring Gmbh | Factor xii inhibitors for the treatment of neurological inflammatory disorders |
WO2014207199A1 (en) | 2013-06-28 | 2014-12-31 | Csl Behring Gmbh | Combination therapy using a factor xii inhibitor and a c1-inhibitor |
AU2013202564B2 (en) * | 2008-06-24 | 2015-09-17 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
WO2015193457A1 (en) | 2014-06-18 | 2015-12-23 | Csl Behring Gmbh | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
US9518127B2 (en) | 2011-07-22 | 2016-12-13 | Csl Behring Gmbh | Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses |
US9878017B2 (en) | 2013-04-22 | 2018-01-30 | Csl Ltd. | Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto |
WO2019038350A1 (en) | 2017-08-23 | 2019-02-28 | Csl Behring Gmbh | Method for virus filtration of von willebrand factor |
US10286047B2 (en) | 2013-03-08 | 2019-05-14 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
WO2019218009A1 (en) | 2018-05-16 | 2019-11-21 | Csl Limited | Soluble complement receptor type 1 variants and uses thereof |
WO2020187969A1 (en) | 2019-03-19 | 2020-09-24 | CSL Behring Lengnau AG | Factor ix variants and uses thereof in therapy |
US10829539B2 (en) | 2014-06-13 | 2020-11-10 | Csl Limited | Production of recombinant von Willebrand factor in a bioreactor |
US11174321B2 (en) | 2016-04-06 | 2021-11-16 | Csl Limited | Method of treating atherosclerosis |
EP3710034A4 (en) * | 2017-11-14 | 2022-01-26 | Arcellx, Inc. | Multifunctional immune cell therapies |
US11377482B2 (en) | 2017-11-14 | 2022-07-05 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1088084T3 (en) * | 1998-06-15 | 2007-01-29 | Gtc Biotherapeutics Inc | Erythropoietin analog-human serum albumin fusion protein |
US20030005468A1 (en) * | 1998-06-19 | 2003-01-02 | Meade Harry M. | Methods and vectors for improving nucleic acid expression |
US20040226053A1 (en) * | 2000-10-13 | 2004-11-11 | Meade Harry M. | Methods of producing a target molecule in a transgenic animal and purification of the target molecule |
BRPI0720035A2 (en) * | 2006-12-06 | 2019-05-07 | Medimmune, Llc | methods for treating a patient having a disease or disorder, for treating a patient with autoimmune disease, for neutralizing an ifn inducible type 1 or ifnalfa pd marker expression profile in a patient, for monitoring or predicting autoimmune disease progression of a patient to monitor disease progression of a patient receiving treatment with a therapeutic agent that binds to and modulates ifnalfa activity, to identify a patient as a candidate for a therapeutic agent that binds to and modulates the activity of ifnalfa ifnalfa, to diagnose a patient as having a disorder associated with increased ifnalfa levels, to identify a therapeutic candidate for the treatment of ifnalfa-mediated disorders, and to detect ifn activity in a sample, probe set, and kit |
AU2008219007A1 (en) * | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
JP5411129B2 (en) * | 2007-05-03 | 2014-02-12 | メディミューン,エルエルシー | Interferon alpha-inducible pharmacodynamic marker |
US20100261172A1 (en) * | 2007-05-03 | 2010-10-14 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
WO2010036293A1 (en) * | 2008-09-24 | 2010-04-01 | The Johns Hokins University | Malaria vaccine |
US8420387B2 (en) | 2009-11-06 | 2013-04-16 | Agrivida, Inc. | Intein-modified enzymes, their production and industrial applications |
US10407742B2 (en) | 2009-11-06 | 2019-09-10 | Agrivida, Inc. | Intein-modified enzymes, their production and industrial applications |
US9464333B2 (en) | 2009-11-06 | 2016-10-11 | Agrivida, Inc. | Intein-modified enzymes, their production and industrial applications |
MX2012014975A (en) | 2010-06-22 | 2013-03-12 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3. |
RU2013113723A (en) | 2010-09-14 | 2014-10-20 | Ф.Хоффманн-Ля Рош Аг | HYBRID POLYPEPTIDE WITH A SERPIN FINGER |
CA2823005C (en) | 2010-12-30 | 2019-07-09 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Glycols as pathogen inactivating agents |
EP2879697A4 (en) | 2012-08-03 | 2016-01-20 | Lfb Usa Inc | The use of antithrombin in extracorporeal membrane oxygenation |
JP2016508515A (en) | 2013-02-13 | 2016-03-22 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies | Highly galactosylated anti-TNF-α antibody and use thereof |
TW201446962A (en) | 2013-02-13 | 2014-12-16 | Lab Francais Du Fractionnement | Proteins with modified glycosylation and methods of production thereof |
EP2970921B1 (en) * | 2013-03-15 | 2018-09-19 | aTyr Pharma, Inc. | Histidyl-trna synthetase-fc conjugates |
KR20160029840A (en) | 2013-07-05 | 2016-03-15 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | Affinity chromatography matrix |
DK4176894T3 (en) * | 2014-01-10 | 2024-05-27 | Bioverativ Therapeutics Inc | CHIMERIC FACTOR VIII PROTEINS AND USES THEREOF |
CN109641971B (en) * | 2016-08-25 | 2023-04-04 | Jcr制药股份有限公司 | Method for producing antibody fusion protein |
GB201707715D0 (en) * | 2017-05-14 | 2017-06-28 | Hamlet Pharma Ab | Preperation of biologically active complexes |
EP3638689A1 (en) * | 2017-06-13 | 2020-04-22 | Aalto University Foundation SR | Method for producing a condensed adhesive phase of silk fusion proteins |
ES2923152T3 (en) * | 2017-11-06 | 2022-09-23 | Thena Biotech S R L | Fusion proteins based on human ferritin and peptides cleavable by proteases and their use as chemotherapeutic vehicles |
US20210094995A1 (en) * | 2018-03-05 | 2021-04-01 | The University Of Chicago | Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines |
AU2019270184A1 (en) | 2018-05-18 | 2020-11-26 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
EP3802587A4 (en) * | 2018-06-07 | 2022-03-23 | Prottech Inc. | Pharmaceutical composition containing fusion protein and use thereof |
EP3864024A4 (en) * | 2018-10-10 | 2022-07-06 | University of Washington | Fusion products and bioconjugates containing mixed charge peptides |
CN111499758B (en) * | 2019-01-31 | 2023-01-31 | 中国科学院脑科学与智能技术卓越创新中心 | Method for screening human potassium ion channel modulators |
JP2022522650A (en) * | 2019-03-07 | 2022-04-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | CRISPR-CAS effector polypeptide and how to use it |
CN114555814A (en) * | 2019-09-13 | 2022-05-27 | 罗特格斯新泽西州立大学 | AAV-compatible laminin-linker polyproteins |
CN114430771A (en) * | 2019-09-30 | 2022-05-03 | 丝芭博株式会社 | Protein adhesive, joined body, and method for producing same |
CN111909964A (en) * | 2020-08-25 | 2020-11-10 | 海南医学院 | Method for efficiently expressing AFP3-CASP3 fusion protein |
CN111808881A (en) * | 2020-08-25 | 2020-10-23 | 海南医学院 | Method for efficiently expressing AFP3-PTEN fusion protein |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023472A2 (en) * | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Interferon-beta fusion proteins and uses |
WO2001000855A1 (en) * | 1999-06-23 | 2001-01-04 | Ppl Therapeutics (Scotland) Ltd. | Fusion proteins incorporating lysozyme |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5322775A (en) * | 1986-06-30 | 1994-06-21 | Pharmaceutical Proteins Ltd. | Peptide production |
US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5750172A (en) * | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
AU1228592A (en) * | 1991-01-11 | 1992-08-17 | American Red Cross | Expression of active human protein c in mammary tissue of transgenic animals |
US5831141A (en) * | 1991-01-11 | 1998-11-03 | United States Of America As Represented By The Department Of Health And Human Services | Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter |
AU669484B2 (en) * | 1991-07-31 | 1996-06-13 | Peri Development Applications (1985) Ltd | Transgenic protein production |
US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5639940A (en) * | 1994-03-03 | 1997-06-17 | Pharmaceutical Proteins Ltd. | Production of fibrinogen in transgenic animals |
US5780009A (en) * | 1995-01-20 | 1998-07-14 | Nexia Biotechnologies, Inc. | Direct gene transfer into the ruminant mammary gland |
US6534479B1 (en) * | 1995-01-24 | 2003-03-18 | Martinex R & D Inc. | Recombinant alpha-fetoprotein hybrid cytotoxins for treating and diagnosing cancers |
US5843705A (en) * | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
US5945577A (en) * | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
CA2286366C (en) * | 1997-04-03 | 2008-10-07 | Universite Laval | Transgenic expression in genital tract and sexual accessory glands |
AU2002365974A1 (en) * | 2001-11-20 | 2003-06-10 | Clf Medical Technology Acceleration Program, Inc. | Alpha-fetoprotein peptides and uses thereof |
-
2004
- 2004-09-03 CN CNA2004800307086A patent/CN1871252A/en active Pending
- 2004-09-03 AU AU2004271200A patent/AU2004271200A1/en not_active Abandoned
- 2004-09-03 US US10/933,854 patent/US7550263B2/en not_active Expired - Fee Related
- 2004-09-03 JP JP2006525523A patent/JP2007503838A/en not_active Withdrawn
- 2004-09-03 EP EP04783398A patent/EP1670931A2/en not_active Withdrawn
- 2004-09-03 WO PCT/US2004/029128 patent/WO2005024044A2/en not_active Application Discontinuation
- 2004-09-03 CA CA002537273A patent/CA2537273A1/en not_active Abandoned
-
2006
- 2006-02-28 IL IL174011A patent/IL174011A0/en unknown
-
2009
- 2009-02-27 US US12/394,096 patent/US20100021612A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023472A2 (en) * | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Interferon-beta fusion proteins and uses |
WO2001000855A1 (en) * | 1999-06-23 | 2001-01-04 | Ppl Therapeutics (Scotland) Ltd. | Fusion proteins incorporating lysozyme |
Non-Patent Citations (4)
Title |
---|
CHOU W-C ET AL: 'Expression of Chimeric Monomer and Dimer Proteins on the Plasma Membrane of Mammalian Cells' BIOTECHNOLOGY AND BIOENGINEERING vol. 65, no. 2, 1999, pages 160 - 169, XP002987266 * |
LIAO K-W ET AL: 'Design of Transgenes for Expression of Active Chimeric Proteins on Mammalian Cells' BIOTECHNOLOGY AND BIOENGINEERING vol. 73, no. 4, 2001, pages 313 - 323, XP002987267 * |
MORINAGA T. ET AL: 'Primary Structures of Human Alpha-Fetoprotein and its mRNA' PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (USA) vol. 80, August 1983, pages 4604 - 4608, XP001062510 * |
SCHNIEKE A.E. ET AL: 'Human Factor IX Transgenic Sheep Produced by Transfer of Nucleic from Transfected Fetal Fibroblasts' SCIENCE vol. 278, 19 December 1997, pages 2130 - 2133, XP002900703 * |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007090584A1 (en) | 2006-02-06 | 2007-08-16 | Csl Behring Gmbh | Modified coagulation factor vila with extended half-life |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
US8765915B2 (en) | 2006-02-06 | 2014-07-01 | Csl Behring Gmbh | Modified coagulation factor VIIa with extended half-life |
EP2233576A1 (en) | 2006-02-06 | 2010-09-29 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
EP2004844A2 (en) * | 2006-03-29 | 2008-12-24 | Merrimack Pharmaceuticals, Inc. | Coadministration of alpha-fetoprotein and a disease modifying anti-rheumatic drug for treating inflammatory arthritic disease |
EP2004844A4 (en) * | 2006-03-29 | 2010-06-09 | Merrimack Pharmaceuticals Inc | Coadministration of alpha-fetoprotein and a disease modifying anti-rheumatic drug for treating inflammatory arthritic disease |
WO2007126546A1 (en) * | 2006-03-30 | 2007-11-08 | Cogenesys, Inc. | Fusion proteins comprising alpha fetoprotein |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
WO2007144173A1 (en) | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP3564267A1 (en) | 2006-06-14 | 2019-11-06 | CSL Behring GmbH | Proteolytically cleavable fusion proteins with high molar specific activity |
EP3896090A1 (en) | 2006-06-14 | 2021-10-20 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP2256135A1 (en) | 2006-06-14 | 2010-12-01 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
US8754194B2 (en) | 2006-12-22 | 2014-06-17 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
AU2007338298B2 (en) * | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
EP3231440A1 (en) | 2006-12-22 | 2017-10-18 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
WO2008098720A1 (en) * | 2007-02-12 | 2008-08-21 | Csl Behring Gmbh | Therapeutic application of kazal-type serine protease inhibitors |
US8283319B2 (en) | 2007-02-12 | 2012-10-09 | Csl Behring Gmbh | Therapeutic application of Kazal-type serine protease inhibitors |
EP2526962A1 (en) | 2007-02-12 | 2012-11-28 | CSL Behring GmbH | Therapeutic application of Kazal-type serine protease inhibitors |
AU2009262476C1 (en) * | 2008-06-24 | 2016-06-02 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
US9290561B2 (en) | 2008-06-24 | 2016-03-22 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
US8575104B2 (en) | 2008-06-24 | 2013-11-05 | Csl Behring Gmbh | Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life |
WO2009156137A1 (en) * | 2008-06-24 | 2009-12-30 | Csl Behring Gmbh | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
AU2009262476B2 (en) * | 2008-06-24 | 2014-06-26 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
EP2865760A1 (en) | 2008-06-24 | 2015-04-29 | CSL Behring GmbH | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
AU2013202564B2 (en) * | 2008-06-24 | 2015-09-17 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
WO2011121123A1 (en) | 2010-04-01 | 2011-10-06 | Csl Behring Gmbh | Factor xii inhibitors for treating interstitial lung disease |
US9150638B2 (en) | 2010-04-01 | 2015-10-06 | Justus-Liebig-Universität Giessen | Factor XII inhibitors for treating interstitial lung disease |
EP2371857A1 (en) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
WO2012120128A1 (en) | 2011-03-09 | 2012-09-13 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
US9987328B2 (en) | 2011-03-09 | 2018-06-05 | Csl Behring Gmbh | Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
US9352016B2 (en) | 2011-03-09 | 2016-05-31 | Csl Behring Gmbh | Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
WO2012120124A1 (en) | 2011-03-09 | 2012-09-13 | Csl Behring Gmbh | Factor xii inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
US9624307B2 (en) | 2011-03-09 | 2017-04-18 | The General Hospital Corporation | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
US9856326B2 (en) | 2011-07-22 | 2018-01-02 | Csl Behring Gmbh | Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies |
US9518127B2 (en) | 2011-07-22 | 2016-12-13 | Csl Behring Gmbh | Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses |
US9856325B2 (en) | 2011-07-22 | 2018-01-02 | Csl Behring Gmbh | Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies |
US11345759B2 (en) | 2011-07-22 | 2022-05-31 | Csl Behring Gmbh | Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies |
US10513560B2 (en) | 2011-07-22 | 2019-12-24 | Csl Behring Gmbh | Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies |
WO2013113774A1 (en) | 2012-01-31 | 2013-08-08 | Csl Behring Gmbh | Factor xii inhibitors for the treatment of neurological inflammatory disorders |
US9957329B2 (en) | 2012-01-31 | 2018-05-01 | Csl Behring Gmbh | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
US10973891B2 (en) | 2013-03-08 | 2021-04-13 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
US10286047B2 (en) | 2013-03-08 | 2019-05-14 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
US9878017B2 (en) | 2013-04-22 | 2018-01-30 | Csl Ltd. | Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto |
WO2014207199A1 (en) | 2013-06-28 | 2014-12-31 | Csl Behring Gmbh | Combination therapy using a factor xii inhibitor and a c1-inhibitor |
US10829539B2 (en) | 2014-06-13 | 2020-11-10 | Csl Limited | Production of recombinant von Willebrand factor in a bioreactor |
WO2015193457A1 (en) | 2014-06-18 | 2015-12-23 | Csl Behring Gmbh | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
US11174321B2 (en) | 2016-04-06 | 2021-11-16 | Csl Limited | Method of treating atherosclerosis |
WO2019038350A1 (en) | 2017-08-23 | 2019-02-28 | Csl Behring Gmbh | Method for virus filtration of von willebrand factor |
EP3710034A4 (en) * | 2017-11-14 | 2022-01-26 | Arcellx, Inc. | Multifunctional immune cell therapies |
US11377482B2 (en) | 2017-11-14 | 2022-07-05 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
US11730763B2 (en) | 2017-11-14 | 2023-08-22 | Arcellx, Inc. | Multifunctional immune cell therapies |
WO2019218009A1 (en) | 2018-05-16 | 2019-11-21 | Csl Limited | Soluble complement receptor type 1 variants and uses thereof |
WO2020187969A1 (en) | 2019-03-19 | 2020-09-24 | CSL Behring Lengnau AG | Factor ix variants and uses thereof in therapy |
Also Published As
Publication number | Publication date |
---|---|
EP1670931A2 (en) | 2006-06-21 |
IL174011A0 (en) | 2006-08-01 |
WO2005024044A3 (en) | 2005-06-02 |
CN1871252A (en) | 2006-11-29 |
US20060105347A1 (en) | 2006-05-18 |
CA2537273A1 (en) | 2005-03-17 |
US20100021612A1 (en) | 2010-01-28 |
US7550263B2 (en) | 2009-06-23 |
JP2007503838A (en) | 2007-03-01 |
AU2004271200A1 (en) | 2005-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7550263B2 (en) | Method for the production of fusion proteins in transgenic mammal milk | |
US5959171A (en) | Method for the production of biologically active polypeptides in a mammal's | |
JPH10506013A (en) | Transgenic animals expressing human coagulation factor VIII and von Willebrand factor | |
US20070169211A1 (en) | Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof | |
US9738694B2 (en) | Gene of porcine alpha-s1 casein, a promoter of the same and use thereof | |
US20080004212A1 (en) | Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin | |
US20130131317A1 (en) | Expression of secreted human alpha-fetoprotein in transgenic animals | |
JP4068516B2 (en) | Transgenic mammals and cloned mammals | |
JPH04505710A (en) | Improved expression of polypeptides | |
US20050186608A1 (en) | Method for the production of transgenic proteins useful in the treatment of obesity and diabetes | |
US20030046716A1 (en) | Transgenically produced platelet derived growth factor | |
WO2005079525A2 (en) | A method for the production of transgenic proteins useful in the treatment of obesity and diabetes | |
Velander et al. | TRANSGENIC NONHUMAN MAMMALS PRODUCING FIBRINOGEN IN MILKAND METHODS OF PRODUCING FIBRIN | |
AU2008202456A1 (en) | Transgenic and cloned mammals | |
WO2006062507A1 (en) | Methods of prescreening cells for nuclear transfer procedures | |
MXPA00003839A (en) | NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS | |
AU2004210607A1 (en) | Transgenic and cloned mammals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480030708.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006525523 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2537273 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 174011 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 546144 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004271200 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004783398 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004271200 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004783398 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004783398 Country of ref document: EP |